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The characteristic feature of Alzheimer’s disease (AD) is the presence of extracellular amyloid-beta 
(Abeta) plaques, which are surrounded by activated microglial cells.  Microglial cells during the long 
course of the disease can induce neuroinflammation and drive neurodegeneration. Recent evidence 
indicates that neuroinflammation negatively co-relates with cognitive state in AD. Furthermore it’s 
well accepted now that soluble pre-fibrillar Abeta species, rather than insoluble fibrils, are the most 
toxic forms of Abeta. This hypothesis is supported by the fact that plaque load reaches plateau 
before the clinical onset of AD. 
 We investigated whether membrane microvesicles (MVs) released extracellularly by reactive 
microglia may contribute to AD degeneration. We found that production of myeloid MVs is strikingly 
high in AD patients and in subjects with mild cognitive impairment, and that AD MVs are toxic for 
cultured neurons.  We demonstrated the mechanism responsible for MV neurotoxicity in vitro, using 
MVs produced by primary microglia. We found that MV lipids can promote formation of soluble Aβ 
species from extracellular insoluble aggregates. Moreover we showed that MVs can be carriers of 
neurotoxic Aβ forms that are trafficked to MVs after internalization into microglia. Neurotoxicity of 
MVs was neutralized by the Aβ interacting protein PrP and anti- Aβ antibodies, which prevented 
binding to neurons of neurotoxic soluble Aβ species. Finally, administration of the MV shedding 
inhibitor FTY720 for a period of 6 weeks significantly improved memory performance and reduced 
brain inflammation in APP/PS1 mice. This study identifies microglial MVs as a novel mechanism by 
which reactive microglia contribute to AD degeneration and suggests that FTY720, by inhibiting MV 
shedding can ameliorate the pathophisiology and cognitive defects in a mouse AD model. 
 
 
 
 
                                                                                       1.  SUMMARY 
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2.1 Alzheimer’s disease and its pathology. 
Alzheimer's disease (AD) is the leading cause for dementia in the world.  It is an age-related 
neurodegenerative disorder that affects 7% of people older than 65 years and about 40% of people 
older than 80 years (Glass CK, et al., 2010). In 2010, 36 million people suffered from AD and it has 
been estimated that every year this number increases by 7.7 million patients (Werner P, et al., 
2012). The neuropathological changes of AD has both positive and negative features. Classical 
positive lesions consist of abundant amyloid plaques and neurofibrillary tangles, neuropil threads, 
and dystrophic neurites containing hyperphosphorylated tau (Terry RD, et al., 1991; Mandelkow and 
Mandelkow, 1998; Trojanowski and Lee, 2000; Iqbal and Grundke-Iqbal, 2002; Crews and Masliah, 
2010), that are accompanied by astrogliosis (Beach et al., 1989; Itagaki et al., 1989) and microglial 
cell activation (Rogers et al., 1988; Itagaki et al., 1989;Masliah et al., 1991). Sometimes Congophilic 
amyloid angiopathy (CAA) is also observed. In the hippocampus are also found unique plaque, which 
include Hirano bodies and granulovacuolar degeneration. Hirano bodies are eosinophilic rod-like 
cytoplasmic inclusion, relatively common in the stratum lacunosum of the hippocampal CA1 region 
in the elderly. In the AD patients the number of Hirano bodies is abnormally high (Gibson and 
Tomlison, 1977).  Neuronal loss and synapse loss largely parallel tangle formation, although whether 
tangles are causative of neuronal loss or synaptic loss remains uncertain (Gómez Isla, et al., 
1997; Iqbal and Grundke Iqbal, 2002; Bussière et al. 2003; Hof et al., 2003; Yoshiyama et al., 2007; 
Spires Jones, et al., 2008; de Calignon, et al., 2009, 2010; Kimura et al., 2010). 
                                      
Figure 2.1 Two main lesions in AD, senile plaques (SPs) and neurofibrillary tangles (NFTs). Two types of SP diffuse plaques 
with exracellular amyloid deposits and neuritic plaques consist of degenerating neuronal processes with tau paired 
helical filaments along with reactive astrocytes and microglia. (Alberto Serrano-Pozo, et al., 2011) 
Diffused Plaque Neurite Plaque Neurofibrillary Tangles 
                                                                               2.  INTRODUCTION              
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 2.2 Cellular metabolism of Amyloid precursor protein (APP). 
APP is a type I membrane protein and follows the conventional secretory pathway from the 
endoplasmic reticulum (ER) to the plasma membrane. During this process, APP undergoes several 
co-and post-translational modifications, including N-and O-glycosylation, tyrosine sulphation, and 
phosphorylation. Already on the way to the cell surface, APP can undergo endoproteolytic 
processing by secretases and soluble variants of APP are generated which are secreted 
extracellularly. The Aβ domain is located within APP at the junction between the intraluminal and 
transmembrane domains. Two enzymatic steps liberate Aβ from APP. In the first “β-cleavage” step, 
β-site APP-cleaving enzyme (BACE-1) (Vassar et al., 1999) cleaves APP at or near the N-terminus of 
the Aβ peptide; then, in the second, or “γ-cleavage” step, the membrane-bound C-terminal APP 
fragment (CTF) generated by BACE-1 is cleaved by the γ-secretase, a multimeric complex thought to 
be made up of an essential quartet of transmembrane proteins—presenilin 1 (or 2), nicastrin, 
anterior pharynx-defective phenotype 1 (APH-1) and PS-enhancer 2 (PEN-2) (Edbauer et al., 2003). 
Alternatively, APP can be subjected to the proteolytic cleavage by α-secretase, which occurs within 
the sequence of Aβ, thus precluding the formation of the amyloidogenic fragments. α-Secretase 
gives rise to the secretion of the neuroprotective sAPPα fragment and to a C-terminal stub that is 
then cleaved by γ-secretase. Thus APP is processed in two different catabolic pathways: a minor 
amyloidogenic pathway, in which APP is cleaved by β- and γ-secretases releasing Aβ peptide and a 
predominant (> 90%) non-amyloidogenic pathway in which the protein is successively cleaved by α- 
and γ-secretases precluding production of Aβ. APP after its synthesis in the endoplasmic reticulum 
is then transported through the golgi apparatus to the trans golgi network, where the highest 
concentrations of APP are found in neurons (Xu H, et al., 1997; Hartmann T, et al., 1997; Greenfield  
JP, et a.,1999). From there, APP can be transported in secretory vesicles to the cell surface where α-
secretases are located.   
The functions of the APP and its various metabolites is not yet clear, but there is a lot of literature 
that indicates its role in neurite outgrowth, synaptogenesis, neuronal trafficking along the axon, 
transmembrane signal transduction, cell adhesion, as well as in the control of gene expression and 
calcium metabolism, which is essential for synaptic transmission (Berridge, et al., 1998). Disruption 
of calcium homeostasis is considered the common pathway for aging and AD (Khachaturian, et al., 
1989). Amyloidogenic Aβ has been suggested to function as ion channel regulator and as a 
transcriptional activator (Ohyagi, et al., 2005; Pearson and Peers, 2006; Hardy, 2007; 
7 
 
Bailey et al., 2011).  Indeed APP intracellular domain (AICD) is able to regulate transcription of 
several genes, including APP itself, the β-secretase BACE-1 and the Aβ-degrading enzyme neprilysin 
(Cao and Sudhof, 2001; Pardossi Piquard, et al., 2005; Müller et al., 2007; Belyaev et al., 2009, 2010). 
 
 
                                                                                                                                       
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Amyloidgenic pathway of Abeta . 
Generally, amyloid refers to misfolded peptides or proteins that demonstrate a stable, cross-beta 
super-secondary structure that renders the proteins insoluble, fibrous-like, and resistant to 
proteolysis. Each type of amyloidosis is classified according to clinical signs and the main peptide or 
protein that constitutes the amyloid fibrils. Amyloidosis deposits contain not only fibrils but also 
Figure2.2 The amyloidogenicand non-amyloidogenic pathways of amyloid precursor protein (APP) processing and its 
metabolites. Ab, amyloid b-peptide; sAPPa and sAPPb, N-terminal shed ectodomains of APP; CTFa and CTFb, C-terminal 
fragments of APP produced by the actions of a- or b-secretases, respectively; AICD, APP intracellular domain; p3, 
fragment of APP after cleavage by a- and c-secretases; NEP, neprilysin. (J.-N. Octave et al. 2013) 
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nonfibrillar components such as glycosaminoglycans (GAGs), apolipoprotein E (apoE), and serum 
amyloid P (SAP) components. 
 Aβ is an aggregated protein deposited within plaque cores found in AD brain. The Aβ monomers 
are generated in most of the body's cells, including vascular endothelial cells (Kitazume S, et al., 
2010) thyroid epithelial cells (Schmitt TL, et al., 1995) and neuronal and nonneuronal cultured cells. 
However, neuronal cells seem to generate greater amounts of Aβ than other cell types (Fukumoto 
H, et al., 1999). In its monomeric form, this protein is harmless (Giuffrida ML, et al., 2010). 
Aβ monomers form a random coil or α helix conformation transmitted to a β hairpin. This structure 
facilitates polymerisation reaction which triggers monomer polimerization to short, soluble, 
metastable intermediates called oligomers. Oligomers self can be rapidly extended by monomer 
addition to form curvilinear protofibrils. Finally, protofibrils are bundled together to form the large, 
insoluble, cross β-sheet fibrils which accumulate in plaques. Steps within the Aβ aggregation 
pathway are reversible, such that deposited fibrils could give rise to soluble oligomers and 
intermediates. Among Aβ peptides, Aβ 1-42 and pyroglutamate-modified Aβ very rapidly aggregate 
and initiate the complex multistep process that leads to mature fibrils and plaque (Schilling S, et al., 
2006; Bieschke J, et al., 2012).  
 
 
                                      Figure2.3 The Aβaggregation process.  N. Elizabeth Pryor, et al., 2011 
 
2.4 Oligomeric abeta and neurotoxicity. 
Recent evidence suggests that soluble aggregates of Aβ, rather than monomers or insoluble fibrils, 
are responsible for the cellular pathology associated with AD (Caughey B, et al., 2003; Glabe CG, 
9 
 
2006; Roychaudhuri R, et al., 2009). A lot of in vitro studies, done independently by different groups, 
showes that soluble aggregates, formed by synthetic Aβ1-40 and Aβ1-42, induce cellular dysfunction 
and toxicity in cultured cells (Lambert MP, et al., 1998; Gonzalez-Velasquez F.J., et al. 2008; Hartley 
DM, et al., 1999) whereas in vivo, Aβ dodecamers (Aβ-56) isolated from the brains of transgenic AD 
mice were shown to induce memory deficits (Lesne S, et al., 2006). Furthermore, soluble Aβ 
aggregates generated in cell culture drastically inhibit hippocampal long term potentiation in rats 
(Walsh DM, et al., 2002) while there is a poor correlation between the levels of insoluble Aβ fibrils 
and AD severity, in mouse models (Westerman M, et al.,2002). Thus, it is widely accepted that 
soluble Aβ oligomers rather than insoluble fibrils impair cognitive function. The toxicity of small 
soluble Aβ species has been proposed to depend on their interaction with specific neuronal 
proteins, such as the NMDA receptor (Snyder EM, et al.,2005) or the prion protein PrPC (Lauren J, et 
al.,2009), which modulates NMDA receptors through Fyn kinase (Um JW, et al.,2012). Alternatively, 
soluble Aβ oligomers may damage neurons by binding to multiple membrane components, including 
lipids, thereby changing membrane permeability and causing calcium ion leakage into the cell 
(Benilova, et al., 2012; Verdier Y, et al., 2004). 
 
2.5 Alzheimer’s Disease and genetics 
In less than 5% of the cases, AD is inherited as an autosomal dominant trait, and results from 
mutations in the APP gene or in the presenilin (PS) genes (Tanzi, et al., 1996; Hardy, 1997; Tanzi and 
Bertram, 2005) encoding PS1 or PS2, the catalytic subunits of the γ-secretase multiprotein complex 
(De Strooper,2003; Edbauer, et al., 2003). In these inherited AD cases, Aβ production is substantially 
enhanced and plays a key role in the etiology of the disease. Following the amyloid cascade 
hypothesis (Hardy and Selkoe, 2002; Goate and Hardy, 2012), accumulations of Aβ, especially an 
increased ratio of Aβ42: Aβ40, are the initial triggers for the disease process.  
ApoE is a major lipoprotein in the brain and mediates transport of cholesterol and other lipids 
between neurons and glial cells. Importantly, ApoE is also linked to the metabolism of Aβ by 
affecting its aggregation in and clearance from the brain. Inheritance of the apolipoprotein E 
(ApoE4) allele is the major genetic risk factor that is associated with late onset AD (Potter and 
Wisniewski, 2012). Several environmental factors are known as risk factors for Late onset AD 
including, aging, head trauma, type 2 diabetes, hypertension, hypercholesterolemia, and vascular 
pathology.  
10 
 
 
 2.6 Inflammation and Neurodegeneration. 
Microglial cells, which are the resident macrophages of the CNS, play a crucial role in the process of 
neuroinflammation. Microglia have three different morphologies: resting, activated, and 
amoeboid/phagocytic. The healthy, non-inflamed brain contains almost entirely “resting” microglia 
which are highly ramified, with a small, static cell body, but with dynamic and branched processes 
actively surveying the brain parenchyma. In response to any brain alteration (cytokines and many 
signalling molecules produced during acute inflammation) microglia transform from a ramified to 
an activated phagocytic morphology, and start releasing pro-inflammatory mediators. During 
chronic neuroinflammation, these cells can remain activated for extended periods, releasing large 
quantities of cytokines and neurotoxic molecules, which contribute to long-term neuro-
degeneration (Liu and Hong, 2003).However recently it has become apparent that the microglial 
activation is a more dynamic and diverse process than it was considered previously. Indeed, 
depending on the type and duration of the stimulus that microglial cells receive from the brain 
microenvironment, microglia can acquire different functional state and change their phenotype 
during the disease progression. The two opposite phenotypes that microglia can acquire among 
different activation states are usually called M1 proinflammatory phenotype, and M2 phenotype. 
M1 (or classically activated) microglia are effector cells which produce an aggressive first-line 
immune response. M1 phenotype can be induced in vitro by exposure of microglia to interferon 
(IFN)-gamma and tumour necrosis factor α. M2 (or alternatively activated) microglia have instead 
roles in wound healing and in promoting tissue repair. M2 phenotype can be induced in vitro by 
exposure to anti-inflammatory cytokines, such as IL-4 and IL13. Microglia express the two classes of 
major histocompatibility complex, MHC class 1 and MHC class 2, and although these antigen 
presenters are mainly involved in the reaction to infectious disease, they are thought to play a role 
in the development of neuroinflammation (Al Nimer, et al., 2011). Depending on the pathology, 
different pathways contribute to inflammation processes activated in neurodegenerative diseases. 
Factors released from damaged neurons such as α-synuclein in PD, deposits of amyloid aggregates 
in AD, and SOD1 in ASL trigger activation of microglia which, in turn, release pro-inflammatory 
molecules. Furthermore, inflammation leads to enhanced levels of oxidative stress; astrocytes, 
release ROS and NO that, together with NADPH oxidase stimulation, provoke microglia activation. 
Subsequently, activated microglia secrete signals to recruit CD4+ CD25+ T cells, which directly affect 
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neurons via Fas/Fas–ligand interaction. However, other events, such as mitochondrial dysfunction, 
protein aggregation, glutamate excitotoxicity, and loss of trophic factor support, may promote 
neuronal cell death. For instance, tumor necrosis factor-α (TNF-α), a major pro-inflammatory 
cytokine, activates microglia and cause neurotoxicity in motor neurons. The inflammatory 
mediators such as TNF-α, IL-1β, and IL6 derived from non-neuronal cells including microglia 
modulate the progression of neuronal cell death in neurodegenerative disease. Apoptosis and 
necrosis of neurons result in the release of ATP, which further activates microglia through the 
purinergic P2X7 receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Figure2.4 Different inflammatory pathway involved in neurodegenerative diseases. (Nuzzo D, et al 2013) 
 
 
 
 
2.7 Neuroinflammation promotes neurotoxicity in AD. 
 
Alois Alzheimer himself originally identified inflammation of the brain's glial supporting cells as one 
of the hallmark of AD pathology (Alzheimer et al., 1995). In AD, the inflammatory response involves 
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microglial cells and astrocytes, which surround the amyloid plaques (Wyss-Coray, et al., 2003). Aβ 
inducing local inflammation and amplify neuronal death (Nikolaev et al., 2009). The main pathway 
of glial cell activation by Aβ is through toll-like receptors.  Toll-like receptor activation gives rise to 
an inflammatory response that is beneficial at early stages of disease, decreasing Aβ burden, but 
very detrimental at later stages by increasing inflammation and neurotoxicity (Carrero, et al., 2012). 
 
Indeed ramified, resting microglia exert a protective influence over synaptic excitotoxicity (Vinet, et 
al., 2012) by increasing neuronal adenosine A1 receptors through CXC3CL1 expression (Lauro, et al., 
2010). Conversely A beta-activated microglia contribute to excitotoxic synaptic damage (Medeiros 
et al., 2010). Consistent with the original observation made by Alois Alzheimer Aβ plaques also 
induce astrocytic reactivity (Smits, et al., 2002) and there is strong evidence for the involvement of 
the cytokines IL-1β and TNF-α in astrocyte activation by Aβ oligomers. 
In addition it has been clearly established that Aβ plaques facilitate the movement of components 
of the peripheral immune system such as T cells and macrophages into the brain (Stalder, et al., 
2005) and increased peripheral inflammation is capable of propagating sustained and damaging 
neuroinflammation in a positive feedback loop.  
In human patients the role played by inflammation in neuron degeneration is suggested by several 
lines of evidence: 
i) Subjects with high plaque burden without dementia show virtually no evidence of 
neuroinflammation (Lue LF, et al., 1996).  
ii) Recent PET studies (Edison P, et al., 2008; Okello A, et al., 2009) show an inverse correlation 
between the cognitive status and activation of microglia. 
iii)  Activation of microglia increases linearly throughout the disease course and correlates with 
AD neurodegeneration (Serrabo-Pozo A, et al., 2011).  
Moreover, recent studies demonstrating that variants of TREM2 and CD33, two receptors expressed 
in microglial cells, increase the risk for late onset AD (Okello A, et al., 2009; Hollingworth P, et al., 2011) 
have refocused the spotlight on microglia as major contributing factor in AD. 
Although multiple preclinical evidence indicates that microglia activation promotes neuronal 
dysfunction and neuron elimination (Giulian D, et al., 1996; Fuhrmann M, et al., 2010) and accelerates 
AD progression (Bealnilova I, et al., 2012; Tan B, et al., 2012; Weitz TM, et al., 2012) the molecular 
mechanisms by which microglia exert neurotoxicity remain largely unknown. 
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2.8 Exosomes and Shed Microvesicles (MVs) 
Exosomes are a population of small extracellular membrane vesicles (50-90 nm) released by an 
endocytic pathway. Generation of exosomes occurs inside the lumen of multivesicular bodies 
(MVBs) through budding, fission ad segregation of their membrane. Depending upon their biological 
characteristics, intracellular MVBs either traffic to lysosomes, where they are subjected to 
proteosomal degradation (degradative MVBs), or to the plasma membrane, where they release 
exosomes in the extracellular space (exocytic MVBs) upon fusion with the plasma membrane 
(Mathivanan, et al., 2010). The ESCRT (endosomal sorting complex required for transport) 
machinery, is involved in sorting of vesicles inside MVBs. Fission of exosome membrane is facilitated 
by components of the ESCRT-III complex, called charged multivesicular body proteins (CHMPs); 
(Hanson, et al., 2009; Wollert and Hurley, 2010; Wollert, et al., 2009) and by the AAA-ATPase 
vacuolar protein sorting associated 4, VPS4 (Babst, 2005). There are various other factors that 
promote exosome biogenesis, including the sphingolipid ceramide produced by neutral 
sphingomyelinase (Kosaka, et al., 2010; Trajkovic, et al., 2008). Exosomes are enriched in several 
proteins and lipids of the MVB membrane, and, exosome biogenesis serves as a mechanism of 
regulated assembly of MVB components. Exosomes are enriched in numerous protein involved in 
membrane transport and fusion (i.e. annexin, flotillin, Rab GTPases), in MVB biogenesis (Alix), 
besides other typical molecules such as integrins and tetraspanins (CD63, CD9, CD81, CD82). They 
are also characterized by the presence of high levels of cholesterol, sphingolipids, ceramide and 
glycerophospolipids in their membrane (Simons and Raposo, 2009). 
 
Microvesicles (MVs), sometimes refereed as shed vesicles or ectosomes (Sadallah, et al., 2011), are 
quite large membrane vesicles, more heterogeneous in size (100nm-1μm) and shape as compared 
to exosomes. They bud directly from the plasma membrane, upon cell activation and are released 
into the extracellular environment. A sorting process is involved in shedding of MVs, in which surface 
blebs selectively accumulates cellular constituents that are then packaged into MVs. Depending 
upon the cell of origin, MVs contain a variety of cell surface receptors, intracellular signalling 
proteins and genetic materials. An interesting feature of MVs is that they reflect the differential 
expression of proteins of donor cells and therefore MVs shed from distinct cells are molecularly 
different from each other. Composition and biological activity of MVs also vary depending on the 
state (e.g. resting, stimulated) of donor cells and depending on the agent employed for stimulation 
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(Bernimoulin, et al., 2008). However, in general shed vesicles are characterized by the presence of 
high levels of phosphatidylserine (PS) on their surface. 
 
 
 
                                         Figure2.5 Differences pathway of generation of Exosomes and Shed Vesicles. (Cocucci et al, 2009) 
 
2.9 Pathological and physiological role of MVs. 
MV shedding from the plasma membrane is now recognized as a widespread mode of intercellular 
communication. In addition it is widely accepted that MVs play a role in several physiological and 
pathological process such as cell proliferation, coagulation, vascular function, apoptosis, and 
inflammation and tumour progression. In physiological conditions platelet-derived MVs, by acting 
on macrophages, neutrophils and other platelets work as trigger of coagulation. However, vesicles 
are also present in the lipid core of atherosclerotic plaque where promote thrombotic signals 
(Cocucci et al, 2009). Moreover, vesicles secreted from different cells can influence the immune 
response, for example MVs can present antigen to T cells, or transfer the antigen-MHCII complex to 
dendritic cells, or directly activate natural killer cells and macrophages (Thery, et al., 2009). During 
inflammation MVs can act both as anti-inflammatory or pro-inflammatory mediators. Neutrophil 
derived microvescicles stimulate the production of anti-inflammatory cytokines and MVs released 
from fibroblasts promote the synthesis of pro-inflammatory cytokines, such as inteleukin-6 (IL-6), 
the monocyte chemotactic protein 1 and metalloproteinase. The most well characterized 
membrane vesicles are those released from blood cells, i.e. platelets, leukocytes, erythrocytes, and 
endothelial cells. However, accumulating evidence demonstrate that MVs and exosomes can also 
be released by brain cells and that these particles play an important function in the central nervous 
system (CNS) both in pathologic or healthy conditions. The exosomes derived from 
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oligodendrocytes control myelination, and those produced from Schwann cells support local axonal 
protein synthesis by delivering ribosomes to injured neuron. Moreover exosomes released by 
neuron may contribute to the spreading of pathogenic agents or degenerative proteins like beta-
amyloid and alpha-synuclein (Emmanouilidou, et al., 2010).  
2.10 Activated Microglia secrete shed microvesicles (MVs) in the extracellular matrix. 
MV shedding from microglial cells has been the main research interest of our lab during the past 
years. The size of microglial MVs ranges from 0.1 μm –1 μm. As ectosomes produced by most cell 
types microglial MVs are characterized by high levels of externalized phosphatidylserine in their 
membrane. MV shedding increases upon microglial stimulation with ATP, a typical danger signal, 
and activation of the P2X7 receptors, which are highly expressed in microglia.  MVs produced by 
reactive microglia carry the pro-inflammatory cytokine interleukin-1β (IL-1β), together with the IL-
1β-processing enzyme caspase-1, and the P2X7 receptor (Bianco, et al., 2005), suggesting that they 
contain the main components of the inflammation. The budding of MVs is facilitated by 
externalization of acid sphingomyelinase, which by locally increasing ceramide levels in the inner 
leaflet of the plasma membrane modifies the membrane curvature (Bianco, et al., 2009).  We 
recently showed that reactive microglia through the release of extracellular ectosomes propagate 
an inflammatory signal. Microglia-derived MVs can transmit inflammatory signals to recipient 
microglia, which indeed upregulate the co-stimulatory molecule CD86 and express pro-
inflammatory genes like IL-1β, IL-6, inducible nitric oxide synthase, and cyclooxygenase-2 upon 
exposure to MVs produced by reactive microglia (Verderio, et al., 2012) 
Intriguingly, microglia-derived MVs can also interact with neurons and stimulate spontaneous and 
evoked excitatory transmission both in vitro and after injection in vivo. Hippocampal neurons 
exposed to MVs show an increase in miniature excitatory post-synaptic current (mEPSC) frequency 
without changes in mEPSC amplitude. MVs affect the pre-synaptic site of the excitatory synapse by 
increasing the release probability of synaptic vesicles through induction of ceramide and 
sphingosine synthesis. Thus, microglial MVs appear to modulate synaptic activity and enhance 
neurotransmission (Antonucci, et al., 2012; Turola, et al., 2012).  
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                               Figure 2.6 P2X7R--‐induced MVs shedding in glial cells (Bianco, et al., 2009). 
 
2.11 Clinical Diagnosis in AD and prospective of MVs as biomarker. 
In 1984, a working group established by the National Institute of Neurological and Communicative 
disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association created clinical 
diagnostic guidelines of probable AD (McKhann, et al.,1984), which were validated against 
neuropathological diagnosis with a sensitivity and specificity of around 80 and 70%, respectively 
(Knopman DS, et al., 2001). However, the criteria only allowed diagnosis when the patients were so 
severely affected by the disease process that they could not manage daily functioning in respect to 
intellectual and social abilities. In 2011 there was a revision of these guidelines by a new working 
group from the National Institute of Aging (Jack CR Jr, et al., 2011). Because of these new imaging 
techniques and the analysis of cerebrospinal fluid (CSF) biomarkers it is also possible to make a pre-
dementia diagnosis of AD. The CSF biomarkers included in diagnostic criteria include the total 
amount of tau (T-tau), which reflects the intensity of neuroaxonal degeneration, P-tau, which may 
correlate with tangle pathology, and the 42 amino acid amiloidogenic peptide Aβ42, which 
correlates inversely with plaque pathology (Blennow K, et al.,2010). It is well known that the 
pathological processes in the brains of AD patients start more than a decade before the first 
symptoms are noticed (Price JL, et al., 1999). The temporal dynamics of biomarker levels in relation 
to changes in cognition have been described in a hypothetical model on the continuum of AD (Jack 
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CR Jr, et al., 2010). In line with this, the revised diagnostic guidelines identify three different stages 
of AD: preclinical AD, mild cognitive impairment (MCI) or prodromal AD and AD with dementia.  
MVs are emerging as important diagnostic tool and therapeutic target (Cocucci, et al., 2009). 
Because of their small size, released MVs can move from the site of discharge and enter into 
biological fluids. MVs have been detected in almost all body fluids, including plasma, urine, milk, 
and the CSF (Camussi, et al., 2010). The presence of MVs in body fluid make them easy accessible 
and it has been suggested that the analysis of their concentration and molecular composition can 
open a window on the damaged tissue (Camussi, et al., 2010). Notably, recent findings of our 
laboratory identified microglia-derived MVs in the CSF as a novel biomarker of brain inflammation 
(Verderio C, et al., 2012; Colombo E, et al., 2012), which reflect the extent of microglial activation in 
patients with neuroinflammatory diseases .   
Remarkably, typical proteins of EMVs, like flotilin, have been detected in the plaques of AD brain 
(Rajendran L, et al., 2006). Altogether these observations suggested that MVs may be involved in 
the spatiotemporal propagation of AD pathology throughout the brain, this possibility is recently 
demonstrated where misfolded tau and Aβ have been shown to propagate through the extracellular 
space and disrupt neuronal systems (de Calignon Alix, et al., 2012; Harris et al., 2010). Intrastatial 
injection of synthetic misfolded α- Syn led to the cell-to-cell transmission of pathologic α-Syn and 
Parkinson's-like Lewy pathology in wild type mice with progressive loss of dopamine neurons in the 
substantia nigra (Luk KC, et al., 2012). 
2.12 Cross-talk of membrane lipids and Alzheimer-associated proteins.  
 In the last years, several molecular mechanisms have been identified that connect membrane lipids 
to the metabolism of AD related proteins, in particular Aβ generation and aggregation. Indeed, 
researchers have found that Aβ is produced in cholesterol-rich and detergent-resistant membrane 
microdomains of the plasma membrane, which are known as lipid rafts. So far studies have mainly 
focused on the role of cholesterol and sphingolipids on abeta processing. It has been clarified that 
alterations in the membrane lipid composition affect secretase activities, thereby modulating APP 
processing and generation of Aβ. In addition, it has been reported that membrane lipids impair the 
metabolism of tau. However, evidence was also provided that membrane lipids can directly interact 
with Aβ and modulate its aggregation. Thus, the two neuropathological hallmarks of AD, abeta 
plaques and neufibrillary tangles, could be both triggered by age-dependent changes in lipid 
metabolism. Conversely, membrane lipid composition is affected by APP and its derivatives Aβ and 
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CTFβ, which were shown to modulate lipid metabolic enzymes and directly bind membrane lipids 
including cholesterol and gangliosides. Tau also affects membrane lipid composition, likely via 
regulation of vesicular transport. Finally, ApoE as a major lipoprotein in the brain, also affect lipid 
composition, but also Aβ clearance and aggregation. These findings suggest a close interaction of 
metabolic pathways related to APP and membrane lipids. Hence, accumulating evidence indicate 
that alterations in secretase activities as well as dysregulation of lipid metabolic enzymes might 
underlie the initiation and progression of AD pathogenesis. 
 
2.13 Membrane lipids: as Platform for Amyloid aggregation and/or destabilization 
Recent biochemical studies indicated that natural sphingolipids and gangliosides, whose 
metabolism has been shown to be altered in AD patients (Mielke MM, et al., 2011), destabilize and 
rapidly resolubilize long Aβ fibrils to neurotoxic species (Martins IC, et al., 2008). These studies also 
showed that phospholipids stabilize toxic oligomers from monomeric peptides (Johansson AS, et al., 
2007). The interaction between Aβ and the cholesterol is inversely correlated with the extent of the 
peptide-peptide interactions (Zhao LN, et al., 2011). The depletion of cholesterol or gangliosides has 
been shown to significantly reduce the amount of Aβ and its accumulation (Wakabayashi M, et al., 
2009, 2005). In fact, the aggregation of Aβ to fibrills is mediated by the gangliosides on the lipid 
rafts, where a transition from the alpha-helix-rich conformation to the β-sheet-rich conformation is 
observed. Thus, the constituents of the raft-like membrane strictly control the amyloid formation. 
MVs which are derived from microglia cells, as a matter of fact should have similar membrane 
composition as its donor cells, therefore the membrane lipids of these MVs can serve as a platform 
to influence amyloid conformations and possibly play a defined role in AD pathology. 
 
 
 
 
  
 
 
Figure 2.7 Model to describe MVs sphingolipids/ ganglioside induced alterations in  the equilibrium of abeta aggregation 
pathway towards soluble non filrillar Aβ species. 
A fibrils Soluble prefibrillar A  
MVs sphingolipids/  
 gangliosides 
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2.14 FTY720: a MV shedding inhibitor 
Fingolimod, FTY720, trade name Gilenya, is a pharmacological drug from Novartis. Fingolimod was 
synthesized by modifying myriocin, which is derived from Isaria sinclairi, an entomopathogenic 
fungus. The drug is a structural analogue of the natural sphingolipid sphingosine. After oral 
administration, fingolimod crosses the blood−brain barrier (BBB), because of its lipophilic nature 
and gets phosphorylated by sphingosine kinase producing P-fingolimod, which then binds to the S1P 
receptors (S1P1,3−5) and exerts its biological action. Levels of fingolimod and active P-fingolymod 
have been shown to be higher in the brain compared to blood (Miron V, et al., 2008).  The S1P 
receptors play key roles in the immune system including regulating lymphocyte migration from 
lymphoid tissue into circulation. By binding the S1P receptors, fingolimod prevents lymphocyte 
egress from lymphoids, thereby reducing lymphocyte infiltration into the CNS (Miron V, et al., 2008). 
Therefore, fingolimod phosphate (FTY720-P) prevents autoreactive lymphocytes from infiltrating 
the central nervous system (CNS) and suppresses subsequent neuroinflammation. Because of this 
property, fingolimod is a new oral drug for multiple sclerosis (Cohen JA, et al., 2011). Recent reports 
suggest that FTY70 is an inhibitor of A-SMase (Dawson G, et al., 2011), the enzyme that controls MV 
production. Consistently, work from our lab demonstrated that FTY720 completely abolished ATP-
induced MV shedding from primary mouse microglia and strongly reduced production of myeloid 
MVs in the CSF of mice affected by EAE, the mouse model of human multiple sclerosis (Verderio C, 
et al., 2012). 
           
                                                                                       Figure2.8 Structure of FTY720 
 
2.15 FTY720 and neuroprotection in AD 
Reduced levels of S1P have been reported in AD patients as compared with the age-matched normal 
controls. In addition, it has been demonstrated in an ex vivo study, that S1P possesses 
neuroprotective effects against cell death induced by soluble Aβ oligomer by inhibiting the 
activation of acid sphingomyelinase (Gómez-Muñoz, et al., 2003). Accordingly, SPK1 (S1P producing 
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enzyme) overexpression, has been described to promote neuronal survival upon Aβ exposure 
(Gomez A -Brouchet, et al., 2007).  
It has recently been described that FTY720 protects from Aβ neurotoxicity both in vitro and in vivo 
(Doi Y, et al. 2013; Fatemeh Hemmati, et al. 2013; Asle-Rousta M, et al 2013). Chronic treatment for 
5 days with FTY in rats which received single intra-hippocampus injection of Aβ 1-42 peptide, was 
observed to prevent hippocampus neuronal death along with p-38 over transcription. (Fatemeh 
Hemmati, et al. 2013). There was reduced neuroinflammation as determined by the diminished IL-
1β and TNF-α mRNA levels (Fatemeh Hemmati, et al. 2013). Consistently, FTY720 administration in 
rats subjected to bilateral intra-hippocampal injection of Aβ 1-42 peptide, for 15 days, significantly 
decreased activity of caspase-3, in hippocampus and decreased neuronal loss in the CA1 area, 
induced by Aβ 1-42 (Asle-Rousta M, et al 2013). The protective actions of FTY720 also improved 
spatial learning and memory formation in these rat models (Fatemeh Hemmati, et al. 2013; Asle-
Rousta M, et al 2013).This protective action of FTY720 may be ascribed to the capability of FTY720 
to recapitulate the function of S1P and regulate the ceramide/S1P balance, as FTY720 decreases the 
levels of ceramides (S. Lahiri, et al.2009). However, recent reports also suggest that FTY720 may act 
directly on neural and non-neural CNS cells to reduce neurodegeneration and to promote reparative 
mechanisms by upregulating BDNF, a neurotrophin which is known to attenuate oligomeric Aβ-
induced neurotoxicity (Doi Y, et al. 2013).  
 
2.16 APPswe/PS1dE9 as AD mice model to study neuroinflammation and behavioural defects 
APPswe/PS1dE9 mice, described by Jankowsky et al. in 2004, have overexpression of the Swedish 
mutation of APP, together with deletion of exon 9 in PS1 (Jankowsky J L, et al., 2004) Overexpression 
of the transgene construct leads to increase in parenchymal Aβ load. APPswe/PS1dE9 mice develop 
first Aβ plaques at the age of 4 months. As the plaque grows activated microglia and astrocytes 
surround them. By 12 months of age, the mice develop cognitive defects, as indicated by behavioral 
test measuring spatial navigation and reference learning, the Morris water maze (MWM) task, but 
memory deficits can be seen in radial arm water maze even at 6 months of age (Xiong H, et al.,2011). 
These mice do not exhibit neuronal loss, but display a variety of other clinically relevant AD-like 
symptoms. These include mild abnormalities in neuritis (Garcia M-Alloza, et al.,2010) loss in 
neuronal activity associated to plaque (Meyer M –Luehmann ,et al., 2009), increased mortality, high 
prevalence to unprovoked seizures (Minkeviciene R, et al., 2009),  age-dependent deficits in the pre- 
and postsynaptic cholinergic transmission (Machová E, et al., 2010), and co-relation of the soluble 
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Aβ levels with behavioural deficits at 12 months of age which are comparable to some clinical AD 
cases (W Zhang, et al.,2011). Therefore, these mice represent a valuable tool to study new 
therapeutic approaches targeted specifically against the plaques and plaque related 
neuroinflammation. (Xiong H, et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
 
 
3.1 Primary Culture and Animal Model 
Mixed culture of primary cortical and hippocampal astrocytes were isolated from rat microglial cells 
which were established from E21 rat embryos and were maintained as described by Bianco F, et al., 
2005. The transgenic mice model APPswe/PS1dE9 used, have overexpression of the Swedish 
mutation of APP, together with deletion of exon 9 in PS1 (Jankowsky J L, et al., 2004). The animal 
colony was provided by Dr. Annalisa Buffo, University of Turin Neuroscience Institute of Turin, Italy.  
The number of animal used and their suffering was minimized as much as possible, in accordance 
to the European Communities Council Directive of September 20, 2010 (2010/63/UE). All animal 
handling procedures were performed in accordance to the guidelines of the Institutional Animal 
Care and Use Committee of the University of Milan.  
3.2 Vesicle Isolation by Differential Centrifugation 
Microglial cells were deeply washed with PBS at 37°C. For MV shedding, microglia was stimulated 
with ATP (1mM) for 30mins in Krebs-Ringer solution (KRH, 125mM NaCl, 5mM KCl, 1.2mM MgSO4, 
1.2mM KH2PO, 2mM CaCl2, 6mM D-glucose, and 25mM HEPES/NaOH, pH 7.4) at 37°C and 5% CO2.. 
The supernatant was then withdrawn and subjected to differential centrifugation at 4 C° as follows 
(all steps at 4°C): 2 times for 10 min at 300g to discard cells and debris (P1 pellet); supernatant, 20 
min at 1,200g to obtain P2 vesicle fraction; supernatant, 30 min at 10,000g to obtain P3 vesicle 
population; supernatant, 1h at 110,000g to obtain P4 vesicles.  For biochemical fractionation of 
MVs, total lipids were extracted through the method previously described (Riboni, et al., 2000) with 
2:1 (by volume) of chloroform and methanol. The lipid fraction was evaporated under a nitrogen 
stream, dried for 1 h at 50°C and resuspended in PBS at 40°C in order to obtain multilamellar 
vesicles. Small unilamellar vesicles were obtained by sonicating multilamellar vesicles, following the 
procedure of Barenholz, et a., 1977. 
3.3 A-1 42 Preparations  
A (Anaspec, Fremont, CA) was prepared at a concentration of 2 mM in dimethyl sulfoxide (DMSO) 
that was maintained at 4°C.The lyophilised protein was properly suspended till there was a clean 
solution and was aliquoted. The aliquot stocked at -80°C was directly diluted to 4µM in neuronal 
                                                             3.   MATERIAL & METHODS 
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medium and kept overnight at 37°C. This A 1-42 preparation was used as aggregated A 1-42 in the 
experiments, and was different from fibrillar A 1-42 preparation, consisting of more mature and 
stable fibrils. 
The soluble and fibrillar A1-42 were prepared by initially dissolving it in 100% 
hexafluoroisopropanol (HFP) (Sigma, St Louis, MO, USA) to obtain a 1 mM solution to deseed any 
aggregated protein and obtain a monomeric A 1-42 . It was aliquoted in a sterile microcentrifuge 
tubes. The HFP was allowed to dry overnight in chemical hood and finally the remains of HFP was 
removed under vacuum using a SpeedVac and the peptide film was stored (desiccated) at −80 °C. 
Soluble A 1-42 was prepared as described by Klein et al. Briefly the peptide film was freshly 
resuspended in 100% DMSO to 5mM, it was further diluted to 100M in F-12 medium (Invitrogen, 
Paisley PA4 9RF, UK) and incubated for 24 h at 5°C. Following the incubation it was further 
centrifuged at 14,0000g for 10 min at 4°C to obtain only the soluble forms in the supernatant. For 
fibrillar A1-42 preparation, A or Hylite-488- A peptide film freshly resuspended in DMSO was 
further diluted to 100µM in 10mM HCl (De Felice FG, et al., 2008). It was vortexed for 15sec and 
incubated for 24 h at 37°C. After incubation, it was diluted to 4µM in neuronal medium to be used 
for the experiment. By transmission electron microscopy the aggregation state of A1-42 
preparation was assessed with a Tecnai G2 T20 Twin microscope (FEI, Eindhoven, The Netherlands).  
3.4 Thioflavin T Assay  
A preparations (peptide or fibrillar) were incubated with or without MVs, were diluted to 4µM in 
KRH and incubated overnight at 37 °C. In case of artificial liposomes and microglial MVs lipids A 
preparations 4µM (peptide or fibrillar) where incubated overnight in incubator. For Thioflavin-T 
(ThT) assays, ThT (Fisher Scientific, Waltham, MA) powder was re-suspended in distilled water to 
10mM stock. It was then filtered and diluted to 10M and was added to the A preparations and 
monitored in a Perkin-Elmer LS50 spectrofluorometer. ThT fluorescence emission spectra were 
recorded between 465 and 565 nm with 5 nm slits, using an excitation wavelength of 450 nm. For 
the time-course experiments, the samples were kept at 37°C and aliquots of 100µl were removed 
from the sample at each time point.  
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3.5 Measurement of fluorescent fibrils by confocal microscopy 
Atagged with Hylite-488 (Anaspec, Fremont, CA) was used to prepare fibrils, as described 
previously. The fibrils incubated or not incubated overnight with MVs were exposed for 1h to 2 
weeks old hippocampal neuronal culture plated on glass coverslips. Neurons were then fixed and 
stained in blue for MAP-2. Leica SP5 confocal microscope was used to acquire fluorescence images 
of Afibrils by an operator blinded to the study and analyzed using Image J 1.46r software. 
We then set a fixed threshold on Hylite-488-Apositive images and, having selected the area 
parameter, in m, at 0.1m-infinite in “set measurements”, area of single fibrils was automatically 
measured using “analyse particle” function. The percentage of fibrils charaterized by increasing area 
values - at intervals of 5m2- was calculated and the cumulative distribution plot was constructed 
using OriginPro 8 software. 
 
3.6 Neuronal Cultures and In Vitro Stimulation  
E18 rat pups were used to isolate primary cultures of hippocampal neurons, which where plated 
onto poly-L-lysine-treated coverslips at 520 cells/mm2 cell density and maintained in neurobasal 
with 2% B27 supplement and 2mM glutamine (neuronal medium). Hippocampal neurons DIV 9-15 
were exposed to A 1-42 (4 M), or MVs (1g/100l) isolated from 1million microglial cells and to 
a combination of A 1-42 and MVs for 1h. The combinations of A 1-42, MVs were kept overnight 
at 37C° in incubator incubated in neuronal medium before being exposed to neurons. 1,7X105 
neurons were exposed to MVs produced by 1X106 microglia (microglia: neuron ratio 6:1).  
In a set of neutralizing experiments the mix of A 1-42/MVs  were added with anti-TNF- plus anti-
IL-1 antibodies (R&D Minneapolis, MN) or with the anti-A antibodies 6E10 1:100 (Covance, 
Emerville, CA, USA) plus A11 1:200  (Invitrogen, Life Technologies Ltd., Paisley, UK) or with the prion 
protein PrPC (4M) for 30 minutes before being exposed to cultured neurons.  
3.7 Viability of Cell 
PI/calcein staining. Neuron were stained with calcein-AM (0.5 mg/ml, Invitrogen, Life Technologies 
Ltd., Paisley, UK), propidium iodide (PI) (1μg/ml, Molecular Probes, Life Technologies Ltd., Paisley, 
UK) and Hoechst (8.1 μM, Molecular Probes, Life Technologies Ltd., Paisley, UK) to look for live and 
dead cells in the neuronal cultures. Incubation was performed for 20 min in neuronal medium at 
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37° C and 5% C02. The cells were washed twice with KRH and then were maintained in KRH during 
acquisition of images. Viable cells were positive for Calcein-AM which emits green fluorescence 
signal. Conversely, PI emitted red fluorescence, and was found positive for dead cells as PI could 
reach their nuclei. Fluorescence images were acquired by Leica DMI 4000B microscope, equipped 
with DIC microscopy. We then calculated the ratio of dead cells (PI+ calcein–) to the total number 
of Hoechst stained neurons in and represented it as percentage of neuronal death.  
Annexin-V assay. Incubation with annexin-V-FITC (1:100, BD Pharmingenor, Franklin Lakes, NJ) of 
live neurons was done for 5 min, which were later fixed with 4% paraformaldehyde and in non 
permeabilizing condition were counterstained for the neuronal marker SNAP-25 (mouse anti-SNAP-
25, Sternberger Monoclonals, Baltimora, MD), to preserve annexin-V staining. Fluorescence images 
were acquired by a SPE Leica confocal microscope, equipped with an ACS APO 40x/1.15 oil objective. 
For the analysis of index of neurite density we quantified area of annexin-V+ apoptotic processes by 
Image J 1.46r software and further normalized to SNAP-25 immunoreactive area. 
Cytoplasmic calcium levels. DIV 8-9 old hippocampal neuronal cultures in coverslip were loaded 
with 400l 2M Fura-2/AM (Invitrogen, Life Technologies Ltd., Paisley, UK) in neuronal medium for 
45 min at 37° C. The neurons were washed in KRH and the coverslips were placed in the recording 
chamber of an inverted microscope (Axiovert 100, Zeiss) equipped with a calcium imaging unit. The 
light source used was a Polychrome V (TILL Photonics). Images were collected with a CCD Imago-QE 
camera (TILL Photonics) and analyzed with TILLvisION 4.01 software. The emission of the light was 
acquired at 505 nm at 1Hz, after excitation at 340 and 380 nm wavelengths. The fluorescence ratio 
of F340/380 was expressed as calcium concentration. The ratio values in selected region of interest 
(ROI) corresponding to neuronal somata were calculated from sequences of images to obtain 
temporal analysis. Basal calcium concentration was recorded from at least 100 neurons/condition 
in each experiment. 
 
3.8 Immunocytochemical Staining 
Neurons were fixed with 4% paraformaldehyde and were washed twice with PBS. They were further 
washed three times with low and high phosphate salt buffers. The cells were permeablized with 
1XGSDB. Primary antibodies in 1XGSDB was incubated for 3hrs for the following markers: rabbit 
anti-beta tubulin 1:50(Sigma, St Louis, MO, USA) guinea pig anti-vGLUT-1 1:1000(Synaptic System, 
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Gottingen, Germany), mouse anti-PSD-95 (UC Davis/NIH NeuroMab Facility, CA, USA), mouse anti-
MAP-2 1:1000 (Synaptic System, Goettingen, Germany). The coverslips were washed 3 times with 
high salt buffer. Secondary antibodies in 1XGSDB were conjugated with either Alexa-488, Alexa-555 
or Alexa-633(Invitrogen, Life Technologies Ltd., Paisley, UK) fluorophores in concentration 1:200 and 
incubated for 1hrs. After incubation the cells were washed three times with high salt phosphate 
buffer, and three times with low salt phosphate buffer. The last wash was made in temporal 
phosphate 5mM and the coverslips were mounted and sealed with nail paint, and stored at -20° C 
till they were acquired. For quantification of V-glut-1 puncta per length unit, the length of single 
neuritis was measured using Image J 1.46r software and the number of positive puncta whose 
dimension was greater than 0.01 m was quantified. 
Quantification of Binding of Hylite-488 labeled A (Anaspec, Fremont, CA, USA to neurons 
was quantified using Image J 1.46r software. A fixed threshold was selected in the separate channels 
for Hylite-488-Aand  tubulin staining. Double positive punta were revealed by generating 
double-positive images of Hylite-488-A/ tubulin using “and” option of “image calculator” 
function, The resultant image was then subtracted from Hylite-488-Ausing “subtract” option 
of image calculator and the final image thus obtained represents all the Hylite-488-Apositive 
binding co-localizing with  tubulin. For the analysis the area parameter was selected, in pixels, at 
3-infinite in “set measurements”, total co-localizing area was quantified using “analyse particle” 
function. Total  tubulin fluorescence areawas directly measured in  tubulin fluorescence images, 
after setting a fixed threshold using “analyse particle” function, as described above. Finally, total 
Hylite-488-A/ tubulin co-localizing area was normalized to total  tubulin area in each 
field. tubulin was revealed by Alexa-633 fluorophore, to avoid significant interference of Hylite-
488 in the red channel. Quantification of binding was normalized to  tubulin due to the decrease 
in MAP2 immunofluorescence staining upon AbindingMaximum projection of confocal 
stacks in the x-y plane and z-axis scans were generated using Image J 1.46r software.  
3.9 Western Blotting.  
The lysates of shed MVs and exosomes obtained from Microglial cells, either by ATP induced 
stimulus or through constitutive shedding, were separated by electrophoresis revealed using 
streptavidin (1: 1500, Sigma, St Louis, MO, USA),  rabbit anti-alix (1:1000, Covalab, Billerica, MA, 
USA), mouse anti-Tsg101 (1:1000, Abcam, Cambridge, UK). For western blot analysis of brain cortical 
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samples of transgenic and wild type animals, 50 μg of cortical lysates was resolved on 15% Tri-
Glycine SDS PAGE. The resolved proteins were transferred to nitrocellulose membrane (Millipore, 
San Diego, CA, USA) and then were incubated for 1 h at room temperature with a blocking buffer 
(5% dry milk dissolved in the tris buffered saline with tween-20 (TBST) buffer). The membranes were 
incubated overnight with the primary antibodies for markers GFAP (1:500) and MHCII (1:500) 
incubated for 3 hrs and were washed 3 times with TBST buffer. Secondary antibody for anti- mouse 
HRP was incubated for 1 hr and the membrane was further washed 3 times with TBST (0.1%) and 3 
times with TBST (0.3%). The immunoreactive bands were detected using SuperSignal West Femto 
Pierce ECL (Thermo Fisher Scientific Inc., Rockford, IL) and ECL film (Amersham, GE Healthcare 
limited, UK).  
3.10 Endogenous Glutamate Determination  
High performance liquid chromatography was used to measure endogenous glutamate content. The 
analysis was done following pre-column derivatization with o-phthalaldehyde and then on a C18 
reverse-phase chromatographic column (10 x 4.6 mm, 3 µm; at 30°C; Chrompack, Middleburg, The 
Netherlands) coupled with ﬂuorometric detection (excitation wavelength 350 nm; emission 
wavelength 450 nm) discontinuous triphase gradient separation was done. The internal standard 
was Homoserine (Klein WL, et al., 2002). 
 
3.11 SELDI TOF Mass Spectrometry 
The A isoforms were detected through immune-proteomic assay, and was performed as reported 
previously (De Felice FG, et al., 2008). In short, three microliters of the specific monoclonal 
antibodies (6E10+4G8) (Covance, Emerville, CA, USA) were incubated in a humidity chamber at total 
mAbs concentration of 0.125 mg/mL (concentration of each mAb 0.0625 mg/mL), for 2 h at RT to 
allow covalent binding to the PS20 ProteinChip Array (Bio-Rad, Hercules, CA, USA). Tris–HCl 0.5 M 
pH 8 was used to block unreacted sites, in a humid chamber at RT for 30 min. Spots were washed 
three times with PBS containing 0.5% (v/v) TritonX-100 and then twice with PBS. 5µl of sample was 
used to coat these spots and incubated in a humid chamber overnight. The spots weret washed 
three times with PBS containing 0.1% (v/v) TritonX-100, twice with PBS, and finally with deionized 
water. To the coated spots was added one microliter of α-cyano-4-hydroxy cinnamic acid (CHCA) 
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(Bio-Rad). Using the ProteinChip SELDI System, Enterprise Edition (Bio-Rad) mass identification was 
made. 
 
3.12 ELISA Quantification 
Quantitative determination of A 1-42 and total Tau protein was performed using innotest ELISA kit 
(Innogenetics, Gent, Belgium), according to the manufacturer's procedures. Absorbance was 
detected at 450nm by 1420 Multilabel Counter Victor 2- Wallac, Finland.   
 
3.13 Human Subjects 
CSF from human samples with mild cognitive impairment (n=53), definitive AD (n=89) were obtained 
for diagnostic purposes from subjects according to Dubois criteria, and from age- and sex-matched 
cognitively preserved and neurologically healthy subjects, undergoing spinal anesthesia for 
orthopedic surgery, serving as controls (n=20). The ethical committee of the San Raffaele Scientific 
Institute approved this research project, and all subjects signed written informed consent. 
 
3.14 Quantification and Isolation of MVs from human CSF  
CSF samples were collected by lumbar puncture (200-300l) and flow cytrometric analysis was done 
as described previously (Verderio C, et al., 2012). In brief, CSF from human subjects was stained with 
the myeloid marker IB4-FITC (Sigma, St Louis, MO, USA). The quantification of labeled MVs within a 
fixed time interval on a Canto II HTS flow cytometer and analyzed using FCS 3 software. A vesicle 
gate was determined using side-scatter (SSc) and FSc over the instrument noise (set by running PBS 
filtered through a 100 nm filter). IB4 positive events were evaluated within this gate, (number of 
events/ml) as a parameter of MV concentration. Human MVs were pelletted at 10,000 g from the 
volume of CSF after flow cytometry quantification in experiments, yielding 400 MVs, which is the 
amount produced in vitro by 1X106 microglia. Re-suspension of MVs was done in neuronal medium 
and exposed to 1,7X105 neurons. Alternatively, MVs (10,000 g pellet) were processed and analyzed 
by SELDI-TOF mass spectrometry. 
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3.15 Quantitative real time PCR 
RNA was extracted from cortex of transgenic and wild type mice. cDNA synthesis from total RNA 
was performed using ThermoScriptTM RT-PCR system (Invitrogen) and Random Hexamers as 
primer. IL1-β, iNOS, COX-2, TGFβ and IL-6 mRNA levels were measured by real time PCR using 
Taqman® Gene Expression Assays on the ABI-Prism7000 sequence detection system (Applied 
Biosystems). 50 ng of starting RNA were used as template. The mRNA expression was normalized to 
the levels of GAPDH mRNA. 
 
3.16 Passive Avoidance Test 
In this performance task, there are two compartments in an apparatus, one light and one dark, 
connected via a sliding door. Each mouse was placed in the light compartment and allowed to enter 
the dark compartment, which the mice prefer more than light. In the acquisition trial, the time taken 
to enter the dark compartment was recorded (in seconds).Once the mouse was in the dark 
compartment, the sliding door was closed and an unavoidable electric shock (1mA for 1 seconds) 
delivered via the paws. The animal was then placed back in the home cage, the retention trial was 
carried out 24 h after the acquisition trial, by positioning the mouse in the light compartment and 
recording the time taken to enter the dark compartment (retention latency, cut-off 180 s). An 
increased retention latency indicates that the animal has learned the association between the shock 
and the dark compartment.  
 
3.17 Novel Object Recognition test  
Animals were habituated to the test arena for 10 min on the first day. After 1-day habituation, mice 
were subjected to familiarization (T1) and novel object recognition (T2). During the initial 
familiarization stage, two identical objects were placed in the centre of the arena equidistant from 
the walls and from each other. Each mouse was placed in the centre of the arena between the two 
objects for a maximum of 10 min or until it had completed 30 s of cumulative object exploration. 
Object recognition was scored when the animal was within 0.5 cm of an object with its nose toward 
the object. Exploration was not scored if a mouse reared above the object with its nose in the air or 
climbed on an object. Mice were returned to the home cage after familiarization and retested 120 
min later, and in the arena a novel object (never seen before) took the place of one of the two 
familiar. Scoring of object recognition was performed in the same manner as during the 
familiarization phase. From mouse to mouse the role (familiar or new object) as well as the relative 
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position of the two objects were counterbalanced and randomly permuted. The objects for mice to 
discriminate consisted of white plastic cylinders, colored plastic Lego stacks of different shape and 
a metallic miniature car. The arena was cleaned with 70% ethanol after each trial. The basic measure 
was the time (in seconds) taken by the mice to explore the objects in the two trials. The performance 
was evaluated by calculating a discrimination index (N-F/N+F), where n= time spent exploring the 
new object during T2, F= time spent exploring the familiar object during T2 (Pitsikas, et al., 2001).  
 
3.18 Immunohistochemistry on brain slices 
The brain was embaded in paraffin and slices were taken onto SuperFrost Ultra Plus® glass slides, 
Menzel-Glaser. The sections were deparaffinised with two washes of xylene, 10 minute each. The 
sections were rehydrated in decreasing concentration of ethanol, 99% 95% 70% with 5 minute 
incubation in each dehydration step. Inhibition with peroxidase (3% in dH2O of 30% Hydrogen 
peroxidase) was done for 15 minute, the slides were further washed with PBS buffer for 5 minutes. 
Two more washes were performed with PBST and the sections were blocked with 10% normal horse 
serum in PBS for 30 minutes in humid chamber, at RT. Primary antibody (GFAP and IBA1 in 
concentration 1:900) was incubated for 1 hr in blocking serum, at RT and the sections were further 
washed twice with PBST for 5 minutes. Secondary antibody Vector Lab BA-2000 biotinylated Anti-
Mouse IgG (H+L), made in horse was used at dilution 1:200 in blocking serum, at room temperature 
in humid chamber for 30 minutes. The slides were washed 2 times with PBST. Biotin was complexes 
with peroxidase-labelled avidin, with Vector Lab, Vectastain Elite ABC kit PK-6100 and the reaction 
was carried out for 30 minutes. Slides were further washed with PBST twice. The chromogen 
reaction was carried out with Vector Lab DAB kit for the duration of 5- 10 minutes, depending upon 
the signal. The sections were rinsed with tap water and were counterstained with Mayer’s 
hematoxylin for 1-2 minutes. The sections were again washed in tap water and dehydrated in 
increasing concentration of ethanol, 95%99%. Finally the sections were dehydrated in xylene for 10 
minutes and were further mounted in the coverslip using mounting medium.  
 
3.19 Dot Blot analysis 
Dot blot analysis was done in cortical lysates of APPswe/PS1 using 6E10 antibody. 15 μg of protein 
from cortical tissues was spotted onto a nitrocellulose membrane that was then air-dried. The 
membranes were soaked in 5% milk in TBST, tween 0.01% for 1 h to block non-specific sites and 
were then incubated with the Aβ antibodies 6E10 (dilution 1:1500, mouse monoclonal; Covance, 
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San Diego, CA, USA) for 2hrs, the membrane were washed three times with TBST and then incubated 
with an secondary anti-mouse antibody that was conjugated with HRP (horseradish peroxidase; 1:40 
000 dilution) for 1hr min at room temperature. The membrane was again washed three times with 
TBST and was developed by chemiluminescence reagent SuperSignal West Pierce ECL (Thermo 
Fisher Scientific Inc., Rockford, IL) and ECL film (Amersham, GE Healthcare limited, UK). The analysis 
of dot blot was done by Image J software. 
 
3.20 Statistical Analysis 
The data presented are mean ± SE. SigmaStat 3.5 (Jandel Scientific) software was used to do 
statistical analysis. After testing data for normal distribution, the appropriate statistical test has 
been used, as indicated in legends of figures. The differences were significant if P<0.05 and indicated 
by an asterisk and those at P<0.01 were indicated by a double asterisk.
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4.1 Microglia-derived MVs in combination with A is neurotoxic in vitro 
 Recent evidence claims that natural lipids such as gangliosides and sphingolipids can lead to 
generation of highly toxic Aspecies by altering the equilibrium between insoluble and soluble 
Atowards neurotoxic soluble forms(Martin JC, et al., 2008; Fukunga S, et al., 2012). Given that 
microglia-derived MVs originate from lipid raft domains of the plasma membrane and contain 
bioactive lipids (Antonucci, et al., 2012) we investigated whether MVs may promote A 
neurotoxicity. To this aim, the amyloidogenic peptide A4 M) dissolved in DMSOwas 
incubated overnight with MVs derived from rat primary microglia (1 g/100 l) at 37°C in neuronal 
medium. The neurotoxic potential of Abeta exposed to MVs was then tested on two weeks old 
hippocampal rat neurons. Neurons were incubated with the mix of AandVs or with 
A alone or MVs alone, and neuron viability was then assessed 24 h later by the propidium 
iodide calcein assay (Figure 4.1a). Overnight pre-incubation of Awith MVs led to formation 
of a neurotoxic mixture that significantly increased the percentage of dead neurons. Milder toxic 
effects were observed upon shorter time periods of A pre-incubation with MVs (3-5h).  
  
Figure 4.1 A Overlays of DIC and fluorescence microscopy images of neurons stained for calcein and propidium iodide (PI), after 24 h exposure to 
A1-42MVs mixture or under control conditions. B Percentage of calcein-/PI+ neurons (dead cells) in cultures exposed to Ascrambled 
AMVs or Ascrambled Aincubated overnight withMVs. AA-MVs  (Acutely Added-MVs),freshly isolated MVs added to A 
just before neuron challenge (Kruskal-Wallis ANOVA p<0.001; Dunn’s test for comparison among groups *p<0.05). 
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After overnight incubation MVs alone, A alone do not significantly affected neuronal survival 
(Figure 4.1b). Electron microscopy revealed that after overnight incubation in neuronal medium 
A alone was mainly in a aggregated state (Figure 4.1b). 
No significant increase in the percentage of dead neurons was also observed when MVs were 
incubated with scrambled A. Similarly Aalone supplemented with MVs just before 
neuron challenge (Acutely Added-MVs, AA-MVs) barely affected neuronal viability. Altogether these 
data indicate that pre-treatment of Abeta 1-42 with MVs is necessary to cause neurotoxic damage.  
 
4.2 Neurotoxicity caused by Microglia-derived MVs in combination with A is rapid. 
We observed that the toxicity caused by A pre-incubated with MVs was rapid, as about 15-
30% of neurons loaded with the calcium dye Fura-2 showed an abnormally high level of cytosolic 
calcium, one hour exposure to A pre-incubated with MVs. Basal [Ca2+]i was measured in single 
neurons and expressed as ratio between F340/380 fluorescence (Figure 4.2a-b). We also stained neuronal 
cultures with the early apoptotic marker annexin-V and analysed the neurons positive for the 
annexin-V under the same experimental condition described above. By this approach we confirmed 
that MVs, pre-incubated overnight in neuronal medium with Abeta 1-42, induced a significant 
increase in annexin-V immunoreactivity (Figure 4.2c). 
  
Figure 4.2 A Basal [Ca2+]i was measured in single neurons loaded with the ratiometric calcium dye Fura-2 and expressed as F340/380 fluorescence. 
Representative pseudocolor images of 9DIV control neurons and neurons treated with A1-42/MVs mixture for 1h. The color scale is shown on the 
left, B Quantification of basal [Ca2+]i in neurons exposed to A1-42, MVs or A1-42 in combination withMVs. At least 100 neurons/condition were 
examined. Values are normalized to control (Kruskal-Wallis ANOVA p=0.002; Dunn’s test for comparison among groups *p<0.05). C Quantification of 
early apoptotic damage, revealed by Annexin-V binding, normalized to SNAP-25 immunoreactive area, in neuron. (Kruskal-Wallis ANOVA p=0.001; 
Dunn’s test for comparison among groups *p<0.05. 
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4.3 Microglia-derived MVs in combination with A induces fragmentation of dendrites and 
synaptic loss.  
 Immunofluorescence analysis for the neuronal marker -3 tubulin and the pre- and post-synaptic 
markers V-Glut-1 and PSD-95, was performed in control hippocampal cultures and cultures exposed 
to MVs pretreated with abeta 1-42. We found that the processes of neurons treated with combined 
AandMVs were fragmented. Furthermore the density of excitatory synapses was 
significantly reduced in neurons exposed to abeta and MVs mixture, as indicated by the reduced 
number of vGLUT positive puncta per dendrite length (Figure 4.3a-b). We also observed a 
remarkable decrease in MAP-2 immunoreactivity, which is indicative of dendritic damage (Figure 
4.3c-d). 
 
 
 
 
Figure 4.3 A Confocal microscopy images of 14DIV neurons untreated or pre-treated with A 1-42 in combination with MVs and stained for beta-3 
tubulin, the vesicular glutamate transporter vGlut-1 and the postsynaptic marker PSD-95. Nuclei are stained with Hoechst. Note fragmentation of 
neuronal processes and loss of excitatory synapses in neurons exposed to A1-42/ MVs mixture. Density of excitatory synaptic puncta is quantified 
in B (data follow normal distribution, student T test **p<0.001). C Decrease in immunoreactivity of neuronal marker MAP2, upon extensive binding 
to Hylite-488 A1-42 (right panel) as compared to less A1-42 binding to neuronal process (left). D Enlarged segment of images in panel C showing 
decrease in MAP-2 staining. 
 
4.4 A in combination withMVs causes neuronal damage mainly by excitotoxicity 
The toxic effect of Ain combination withMVs was largely prevented when neurons were 
exposed to Abeta pre-treated with MVs in the presence of the glutamate receptors antagonists APV 
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(100 M) and CNQX (20 M), as evaluated by cytoplasmic calcium recordings. Protection by APV 
was confirmed by evaluation of neuron viability through the annexin-V or PI/ calcein assays 
(Figure4.4 a-c). These observations indicated excitotoxic damage as the cause of neuronal death. 
 
Figure 4.4 A-C Control cultures and cells treated with A1-42MVs mixture analysed for basal [Ca2+]i  (H) (Kruskal-Wallis ANOVA p=0.001; Dunn’s test 
for comparison among groups *p<0.05), early apoptotic damage (I) (Kruskal-Wallis ANOVA p=0.001; Dunn’s test for comparison among groups 
*p<0.05) and calcein/PI staining (J, Kruskal-Wallis ANOVA p<0.001; Dunn’s test for comparison among groups *p<0.05), either in the presence or in 
the absence of the glutamate receptor antagonists APV and CNQX. 
 
4.5 Alterations in the aggregation of Ab1-42 induced by microglial derived MVs. 
Recent evidence suggests that natural lipids solubilize inert A fibrils to neurotoxic 
protofibrillar species. To understand whether overnight incubation with microglial MVs can induce 
alterations in the content of aggregated A we performed the thioflavin T dye-binding assay.  
This assay showed a significant reduction (about 22+ SE %) in the content of abeta fibrils (Figure4.8b, 
red lines) upon overnight incubation with MVs (ref). Furthermore there was a 39+ SE % reduction 
of aggregated Aspecies when a preparation of aggregated A dissolved in DMSO and 
incubated overnight with microglial MVs at 37°c in neuronal medium was exposed to MVs 
(Figure4.5b, blu lines). No changes in Thioflavin-T spectra were detected upon acute MV addition, 
thus excluding possible interference of MV lipids on the Thioflavin-T binding site of A1-42 (Figure 
4.5c). We also performed time course analysis of Aaggregation in the presence or on the 
absence of MVs. Results from time course experiment confirmed that shed MVs solubilize  
aggregated Aand prevent its self-aggregation(Figure 4.5d). Consistent with these 
observations, we found that incubation with MVs reduced the fibril size of fluorescently-labeled 
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A fibrils, which were observed and analyzed by a confocal microscope (Figure 4.5e, left). 
Indeed exposure to MVs induced a shift towards smaller fibril size in the cumulative distribution 
(Figure 4.5e, right). Altogether these observations indicate that aggregated A disassembles 
into soluble species upon MV exposure.  
 
 
 
 
 
Figure 4.5 A Negative staining EM image of aggregated A1-42, incubated overnight in neuronal medium. BThioflavin T emission spectra of 
aggregated Ab 1-42 (solid blue line), incubated overnight with MVs (dashed blue line) or acutely exposed to MVs. C Representative thioflavin-T 
fluorescence emission spectra of samples containing Afibrils (dashed red lines) or aggregated A1-42 (dashed blue lines) exposed to MVs. D 
Time course of fibrilization of A1-42 in the presence (dashed line) or in the absence (solid line) of MVs.  E Representative confocal images of Hylite-
488-A488-A 1-42) fibrils untreated or treated overnight with MVs and exposed for 1h to neurons. Neurons are stained in blue for MAP-2 
after fixation. Cumulative distribution of fibril size from control (solid line) and MV-treated (dashed line) 488-A 1-42 fibril preparations is shown on 
the right. 
 
 
Parallel analysis by SELDI-TOF mass spectrometry using 6E10 and 4G8 anti-A antibodies indicated 
that microglia derived MVs induce a 50% decrease of A1-42 monomers in the amyloid preparation 
(Figure 4.5f), with no significant peptide degradation. This is consistent with oligomerization and 
stabilization of A1-42 monomers in the presence of EMVs, although the absence of antibodies to 
efficiently immuneo-isolate oligomers hampers their direct detection by mass spectrometry. Thus, 
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microglia-derived EMVs may favour solubilization of aggregated A-1-42, but also induce formation 
of soluble oligomers from A1-42 monomers.  
 
 
 
  
 
 
 
 
 
Figure 4.5 F Representative spectra of SELDI-TOF mass spectrometry using 6E10 and 4G8 anti-Ab antibodies indicating decrease in amount of Ab1-42 
monomers in Ab1-42/MVs mix as compared to Ab1-42 peptide alone. 
 
 
4.6 There is a transient interaction of Aβ 1-42 with MVs, but most of the soluble Aβ 1-42 generated 
is free. 
To answer the possibility of interaction of Aβ 1-42 with MVs, Aβ 1-42 forms associated with MVs 
and soluble amyloid forms generated as consequence of this association were separated from 
insoluble species by sucrose gradient centrifugation at 100,000 g for 1 h (Martins JC., et al. 2008) in 
the samples incubated overnight with A/MVs mix. The amount of Aβ 1-42 present was 
quantified by ELISA. We observed a fivefold increase in the fraction of soluble Arecovered at 
the top of the gradient and a parallel decrease in the fraction of insoluble A at the bottom 
of the gradient, upon overnight incubation with MVs (Figure 4.6a). Interestingly acute addition of 
MVs even immediately before ultracentrifugation on sucrose gradient, partially promoted A 
migration to the top of the gradient (Figure 4.6b), suggesting that MVs being light tend to move to 
the top fractions of the gradient and along with associate A and contribute in part to A 
redistribution to the top of the gradient. 
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Figure 4.6 A “Floating assay” by ultracentrifugation reveals an increase of soluble A 1-42 species in association with MVs.. As ELISA indicates, a higher 
fraction of A 1-42 species is transported from the bottom to the top of the gradient in samples incubated overnight with MVs. Acute addition of MVs 
(AA-MVs) does not cause statistically significant changes  in A1-42 distibution (Kruskal-Wallis ANOVA p<0.001; Tukey test for comparison among 
groups *p<0.05 ).  
 
4.7 The neurotoxicity caused by Microglia-derived MVs is retained in the soup. 
MVs incubated overnight with Ain neuronal medium were centrifuged for 30 min at 10,000g 
to obtain a soup and a pellet fractions, with the soup containing soluble molecule released from 
MVs and soluble Aspecies and the pellet containing aggregated A MVs, and 
A forms eventually associated with MVs.  The neurotoxicity of these two fractions was 
analyzed by monitoring cytosolic calcium in cultured neurons. While the pellet was largely inert, 
most of the toxicity was retained in the supernatant (Figure 4.7a left). Similar results were obtained 
by quantification of neuronal death by PI/calcein assay (Figure 4.7a right). These findings suggested 
that soluble molecules not associated with MVs, were responsible for neuronal damage.  
Next we investigated if soluble molecules released from MVs mediate neurotoxicity. We know that 
the inflammatory mediators IL-1 and TNF are among the molecules contained in microglial MVs 
that, through potentiation of NMDA channel activity, may induce excitoxicity (Bianco F, et al., 2005; 
Turola E, et al., 2012). Since IL-1 and TNF expression is up-regulated in M1 proinflammatory 
microglia, and down-regulated in M2 anti-inflammatory cells, neuronal viability was analyzed after 
exposure to A incubated with MVs produced by either LPS-primed M1 microglia or M2 cells, 
polarized with IL-4. We found similar alterations in cytosolic calcium levels in neurons exposed to 
Aincubated with MVs derived from either M1 or M2 polarized microglia as compared to MVs 
produced by resting microglia (Figure 4.7b). In addition, Neuronal cultures were exposed to the 
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neurotoxic mixture in the presence of IL-1 and TNFneutralizing antibodies. There was no change 
in the level of toxicity observed, measured as alterations in cytosolic calcium levels in neurons. 
(Figure 4.7c). These data rule out the possibility that excitotoxicity of A 1-42 in combination with 
MVs depends on cytokine leakage from MVs

Figure4.7 A Basal [Ca2+]i in neurons exposed for 1h either to A1-42MVs mixture or soluble (sup)/insoluble (pellet) fractions (left panel, Kruskal-
Wallis ANOVA p<0.001; Dunn’s test for comparison among groups *p<0.05). Values are normalized to control. Right panel shows the percentage of 
calcein-/PI+ neurons under the same conditions (Kruskal-Wallis ANOVA p=0.002; Dunn’s test for comparison among groups *p<0.05).  B Basal [Ca2+]i 
in neurons exposed for  1 h to MVs derived from resting, M1 or M2 microglia preincubated with extracellular A1-42. Values are normalized to 
control (Kruskal-Wallis ANOVA p<0.001; Dunn’s test for comparison among groups *p<0.05). C Basal [Ca2+]i in neurons exposed to A1-42and/orMVs 
in the presence or in the absence of neutralizing antibodies for IL-1 and TNF. Values are normalized to control. 
 
4.8 The neurotoxicity caused by A 1-42/MVs mixture is due to soluble A forms. 
We then investigated whether neurotoxic soluble A forms could be present in A 1-42/MVs 
mixture. Electron microscopy (EM) analysis revealed globular structures of diameter between 4 and 
8 nm, similar oligomeric A 1-42, together with thin fibrils of short length, likely representing soluble 
protofibrils, in the soup obtained after centrifugation at 10,000g for 30min of the A 1-42/MVs 
mixture. 5-8 nm wide A fibrils were instead observed in the pellet (Figure4.8a). Detection of 
globular/protofibrillar species in the soluble fraction from A 1-42 and MVs mixture, prompted us 
to investigate byan array of techniques whether shed MVs change the equilibrium between soluble 
and insoluble A. (Figure 4.8b) 
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Figure 4.8 Representative TEM images of 5-8 nm wide Ab 1-42 fibrils retrieved in the pellet fraction (A) and of globular Ab 1-42 species, present in 
the supernatant (B) 
 
 
4.9 Bio-detection of the Soluble Agenerated in A 1-42/MVs mixture incubated overnight. 
 
It is known that soluble A but not fibrillar or monomeric A forms activate NMDA receptors, 
enhancing calcium influx through the channel. Therefore we used neurons expressing functional 
NMDA receptors, loaded with FURA-2, as sensor cells to bioassay soluble A 1-42 generated upon 
overnight incubation with MVs. We found that about 30% of neurons showed calcium responses to 
A 1-42 in combination with MVs, but not to A 1-42 or shed MVs alone (Figure 4.9a). Furthermore 
the NMDA receptor antagonist APV (100 M) blocked completely the calcium responses evoked by 
A 1-42 pre-treated with MVs. (Figure 4.9 b-c). HPLC measurements of glutamate content in MVs 
and A 1-42/MVs mixture revealed concentration of glutamate lower than 1 M, which is the 
minimum glutamate concentration able to induce calcium influx in our experimental conditions 
(mean glutamate concentration: 137+ 70 nM, MVs alone; 196+ 115 nM, A 1-42/MVs mixtures). 
This finding exclude possible interference of ambient glutamate in the NMDA-dependent calcium 
response evoked by Abeta and Mvs mixture. We concluded that activation of NMDA calcium 
channels, which triggers neuron excitotoxicity, were caused by soluble A 1-42 species generated 
in the presence of microglial MVs. 
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Figure4.9 Bio-detection of soluble A 1-42 by fura-2-loaded sensor neurons, expressing functional NMDA receptors. Representative traces of [Ca2+]i 
changes recorded in neurons upon exposure to KRH containing A 1-42 alone (4 M) or MVs alone (1gl) or their combination (A). [Ca2+]i  
responses induced by A 1-42/MVs mixture are strongly inhibited by the NMDA receptor antagonist APV (B), as quantified in C. Values represent peak 
[Ca2+]i  increases (ΔF340/380 fluorescence) from about 30 neurons/condition (Kruskal-Wallis ANOVA p<0.001; Dunn’s test for comparison among 
groups *p<0.05). 
 
 
4.10 Microglia derived MVs lipid promote formation of neurotoxic A-1-42 species 
We then investigated whether lipids of shed MVs play an active role in the dissolution of insoluble 
A1-42 species. We observed by thioflavin T assay that exposure to the lipid fraction extracted from 
MVs caused a reduction in amount of fibrillar (f-Ared lines) or aggregated (Ablue lines) A1-42, 
similar to that induced by intact MVs (Figure4.10a). Furthermore, neuron viability analysis revealed 
a similar percentage of dead neurons in cultures exposed to A 1-42 in combination with intact MVs 
or their lipid component (MV lipids, Figure4.10b). Interestingly, A1-42 pre-incubated with synthetic 
liposomes, mimicking the phospholipid composition of the plasma membrane (60% PC, 20% 
cholesterol, 10% SM, 10% PS) and similar in size to MVs did not produce any increase in basal 
calcium concentration (Figure4.10b). These results demonstrated that the lipid component of 
microglial MVs was responsible for the dissolution of insoluble A1-42 species. Thus interaction of 
A1-42 with MVs lipids represents the mechanism by which MVs convert inert A1-42 to neurotoxic 
forms. 
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Figure4.10 A ThioflavinT fluorescence emission spectra of aggregated A1-42 (blue lines) or Afibrils (red lines), untreated (solid lines) or pre-
treated (dashed lines) with shed MVs. Spectra of aggregated A1-42 or Afibrils exposed to MVs lipids (dotted lines) are also shown. B Basal 
[Ca2+]i of neurons exposed for 1h to A1-42pre-treated with intact MVs, small unilamellar vesicles of MV lipids (MV lipids) or artificial liposomes. 
Note that vesicles made by lipids extracted from shed MVs but not artificial liposomes significantly enhance basal [Ca2+]i. 
 
4.11Binding of newly generated soluble A-1-42-488 to neurons is competed by PrPc 
We then visualized soluble A 1-42 forms, generated in the presence of MVs, by imaging their 
binding to hippocampal neurons. To this aim we exposed neuronal cultures for 1h to fluorescent 
A1-42 (488-A1-42), incubated or not overnight with MVs. Quantification of A1-42 fluorescent  
species bound to MAP-2 positive dendrites, revealed that MVs caused a strong increase in the A 1-
42 binding to neurons (Figure 4.11a-b). Notably, binding of 488-A1-42 to dendrites was paralleled 
by a marked reduction of MAP-2 immunoreactivity (Figure 4.11a), in line with previous observations 
(Jana A, et al., 2010). No preferential association of 488-A1-42 with synapses was detected. 
Notably, there was competition between Abinding to dendrites and to PrPc, a high affinity 
receptor for oligomeric A (Lauren J, etal., 2009). This competition resulted in decreased binding 
of soluble A 1-42 forms to cultured neurons.  Furthermore, we observed that soluble A 1-42 
binding can be abolished by pretreatment of 488-A1-42 and MVs mixture with a cocktail of anti-
Aantibodies, i.e. the andantibodiesFigure 4.11 a-b. Unlike the 89-230 truncated PrPC, 
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Figure4.11 A Representative confocal images of 14DIV neurons exposed to 488-A 1-42 alone or in combination with MVs, with or without 
pretreatment with PrP or with the anti-A antibodies A11 and 6E10. B Corresponding quantification of 488-A 1-42 binding to cultured neurons 
expressed as colocalizing area between 488-A and  tubulin, relative to total  tubulin (see methods) (Kruskal-Wallis ANOVA p<0.001; Dunn’s test 
comparison among groups *p<0.05). C-D Basal [Ca2+]i and percentage of calcein-/PI+ neurons in 9-14 DIV cultures exposed to different combinations 
of A 1-42, MVs, A11 plus 6E10 antibodies, full-length or truncated (tPrPC) PrPC (Kruskal-Wallis ANOVA p<0.001; Dunn’s test for comparison among 
groups *p<0.05). 
 both full- length folded PrPC and anti-Aantibodies neutralized the toxicity of A1-42/MVs mixture, 
as revealed by calcium recording (Figure 4.11c) and PI/calcein staining (Figure 4.11d. 
 
 
 
 
 
 
 
 
 
Figure 4.11 E-F Representative confocal images of neurons exposed to the supernatant (sup) (B) or to the pellet (C) fractions obtained after 
centrifugation of 488- Ab 1-42 / MVs mixture. Quantification of binding was performed D.  (ANOVA, p<0.001, Holm-Sidak Method p<0.05). 
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Furthermore we observed that the soup, obtained after pelleting the mix of AVs by 
centrifuging at 10,000g, (speed for pelleting MVs) retained almost 70% of the total A soluble 
species (Figure 4.11e-left,f) that bound to the neuronal processes, and the pellet retained the 
species bound with MVs and more aggregated Aspecies(Figure 4.11e-right,f) 
4.12 MVs carry neurotoxic species generated from internalized A 1-42
Microglia surrounding the amyloid plaques actively phagocyte and degrade A. The MVs released 
from these activated microglia can potentially contain toxic Aspecies, generated from peptides 
internalized during phagocytosis. To investigate this possibility confocal analysis was done with 
microglia exposed to A1-42 for 12-48h. The cells were washed extensively and stained with 6E10 
anti-Aantibody, revealing intracellular A aggregates. We observed that the A1-42 uptake was 
fast. At 12 hr A1-42 was clearly visible inside microglia cells, at 24hr large A1-42 aggregates could  
be observed, a lot of which reached the plasma membrane, and were co-localized with the 
microglial surface stained by the isolectin IB4 (Figure 4.12a).  
 
 
 
 
 
 
 
 
 
 
Figure 4.12 A Living rat microglia were exposed to human A1-42 for 12-48 h and stained with IB4-FITC to label the cell surface beforebeing fixed 
and counterstained with 6E10 antibody, which recognizes human but not rat amyloids Top left panel shows representative xy-plane maximum 
projection of microglia, revealing several 6E10 immunoreactive punctainside the cells, some of which are double positive for surface IB4-FITC.  Bottom 
left panel: single stack of the selected cell, shown at higher magnification, reveals a clear association of internalized A1-42 to the cell surface, further 
revealed by the z-axis scan. Note an increase in the size of internalized A1-42 after incubation for 48 h (top right panel). Examples of EMVs, double 
positive for 6E10 and IB4-FITC are shown in bottom right panels. B Western blot analysis of A 1-42 species present in shed MVs (P2 and P3 fractions) 
and exosomes (P4 fraction) released upon 30 min ATP stimulation by 4X106 microglia pre-exposed to biotinylated A1-42 (4M). Blots were carried 
out using a 15% Tris-glycine gel and membranes were probed with streptavidine. Shed MVs and exosomes produced by 8X106 donor microglia were 
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probed in parallel for the EMV markers Tsg101 and the exosomal marker Alix (lower panels). Numbers below each lane indicate the estimated amount 
of loaded proteins.   
 
Notably, in the extracellular space, close to microglial cells a few Aand IB4 double positive particles 
were detected (Figure 4.12a bottom right panel). These observations suggested that A species can 
be present inside EMVs produced from A-loaded microglia. To verify this possibility we analyzed 
by western blotting the presence Ain MVs released from microglial cells preloaded with 
biotynilated A1-42. To obtain the EMVs, the cells were washed properly after 24 hrs incubation to 
remove the free A1-42, and were kept in ultracentrifuge medium, devoid of any vesicles for the 
next 24hrs to obtained MVs and exosomes released constitutively by microglial cells in the medium. 
After removal of the medium the cells were maintained for some hours in glial medium and were 
further stimulated with ATP for 30 min, a condition which mimics an inflammatory context and 
favours shedding of MVs (P2 and P3 fraction) versus exosome (P4 fraction) release (Bianco F, et 
al.,2009).  Biotin-conjugated A1-42 was recovered in both shed MV, and exosomes which were 
labelled by the EMV markers Tsg101 and Alix (Figure 4.12 b). 
 
 4.13 Internalized A 1-42 is processed by Microglia to other A isoforms, as detected both in MVs 
and exosomes. 
SELDI-TOF mass spectrometry using 6E10 and 4G8 anti-A antibodies showed the presence of A1-
42 and of its cleavage product A1-40, along with traces of other C-terminally truncated isoforms, 
in MVs shed from the plasma membrane (P2+P3 fractions) (Figure 4.13a). Similarly, A1-42 and A1-
40 were recovered in exosomes (P4 fraction), but compared to MVs the amount was ten times less 
(Figure 4.13a).  
By calcium recordings we found that MVs derived from microglia preloaded with 4 M A 1-42 (A-
MVs) were highly neurotoxic as compared to MVs derived from resting cells (Figure 4.13b). 
Neurotoxicity caused by MVs storing A 1-42 was significantly decreased by anti-A antibodies. We 
therefore concluded that microglia internalize and A and sort neurotoxic abeta species to MVs. 
Neurotoxic Abeta species are likely exposed on the external membrane of the MVs, which are 
delivered to neurons and cause neurotoxicity. 
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Figure 4.13 A Shed MVs and exosomes produced by 1X106 rat microglia pre-exposed to human A1-42 were analysed by a SELDI TOF MS 
immunoproteomic assay employing anti-human A antibodies (4G8 and 6E10) on PS20 chip array to capture A1-42 and C-terminally truncated 
abeta isoforms.  The following representative spectra of samples in NP40 1% lysis buffer are shown (from top to bottom): 4M Aβ1-42 peptide 
incubated overnight in KRH; MVs from control microglia, not exposed to Aβ1-42; MVs from Aβ1-42 preloaded microglia (A-MVs); exosomes from 
control microglia (exos);  exosomes from Aβ1-42 preloaded microglia (A-exos). B Basal [Ca2+]i recorded from neurons exposed to MVs produced from 
microglia either resting or pre-treated for 48 h with A1-42 (A-MVs), in the presence or in the absence of anti-A antibodies (A11+6E10) (Kruskal-
Wallis ANOVA p<0.001; Dunn’s test for comparison among groups *p<0.05). See also Figure S1.  
 
4.14 Elevation of Microglia derived MVs in AD patients. 
Recently studies done in our lab indicates that the extent of microglia activation in the course of 
neuroinflammation can be reflected by the amount of microglia-derived MVs detected in the CSF of 
humans (Verderio C, et al., 2012). To understand if the production of MVs from microglia could be 
elevated in AD, where neuroinflamation correlates with cognitive defects, we collected the CSF from 
patients with mild cognitive impairment (MCI) or AD, as well as from age- and gender-matched 
healthy controls (HC). We performed  flow cytometry analysis for MVs positive for the myeloid 
marker IB4 and observed strikingly higher levels (more than ten-fold) of MVs in MCI and AD patients 
than in control subjects (Figure 4.14a). Approximately 65% of total EMVs detectable by flow 
cytometry were IB4-positive. Furthermore, we found that MV concentration correlated with Tau 
protein levels in the CSF, a marker of neurodegeneration (Figure 4.14b; p<0.0001) (Holtzman DM, 
et al., 2011).  
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Figure 4.14A Quantitative flow cytometry analysis of IB4+ MVs in CSF collected from MCI patients (n= 53), AD patients (n = 89), and age- and gender-
matched controls (HC; n= 20) (Mann–Whitney p<0.0001 AD versus HC; p<0.0329 MCI versus HC). B Correlation between IB4+ MVs and total tau protein 
in the CSF of MCI and AD patients, (rho = 0.46, p<0.0001 Spearman correlation). 
 
 
4.15 Microglia derived MVs from AD patient’s effects the equilibrium between soluble and 
insoluble A 1-42 species and cause neurotoxicity. 
 
To verify whether MVs from AD patients affect the equilibrium between soluble and insoluble -
42 specie we collected the CSF from AD patients and isolated MVs by centrifugation at 10,000g. 
Confocal analysis of neurons exposed to 488-A 1-42 pre-incubated overnight with AD MVs revealed 
a three-fold decrease in the content of fluorescent A aggregates (Figure 4.15Ia,b) thus indicating 
that AD MVs break up  insoluble A 1-42 species.  We also observed that AD MVs induced a parallel 
increase in the fluorescent A species bound to dendrites (Figure 4.15Ia,c) 
 
Figure 4.15 I A Representative confocal images of cultured neurons, exposed to aggregated 488-A 1-42 untreated or pre-treated overnight with MVs 
from AD patients and stained for MAP-2 after fixation (red). Aspecies bind to MAP-2 dendrites. Note the decrease in the number of large fluorescent 
Aclusters in neurons exposed to 488-A 1-42 in combination with AD MVs B Quantification of 488-A 1-42 aggregates (larger than 5 m) per field 
(data follow normal distribution, student T test **p<0.001). C Quantification of 488-A 1-42 binding to cultured neurons, expressed as colocalizing 
area between 488-A and tubulin, relative to total  tubulin (see methods) (data follow normal distribution, Student T test **p<0.001). 
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In line with our in vitro results indicating that microglial MVs carry neurotoxic abeta species, we 
demonstrated that MVs recovered from AD patients were highly toxic and eventually lead to 
neuronal death, as quantified by calcein-/PI+ dead neurons. Interestingly MVs isolated from the CSF 
of AD patients were more toxic with respect to MVs isolated from patients with multiple sclerosis, 
(MS) a neuroinflammaory disease characterized by increased level of microglial MVs, (Figure 
4.15IId,e,fThere was a significant decrease in neurotoxicity of AD MVs with pre-treatment with 
anti-Aantibodies, 6E10 and A11 (Figure4.15IIgsuggesting that the toxicity was in part mediated 
by A 1-42 carried by the MVs.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 II D Representative fluorescence microscopy images of 14DIV neurons triple stained for calcein, PI and Hoechst 24 h after exposure to 
ADMVs or maintained in control conditions E-F Quantification of the percentage of calcein-/PI+ neurons (dead cells) in cultures exposed to ADMVs 
or MVs isolated from patients with multiple sclerosis (MS) or Aalone (Kruskal-Wallis ANOVA p<0.001; Dunn’s test for comparison among groups 
*p<0.05). G Percentage of dead neurons in cultures exposed to MVs isolated from the CSF of ADpatientsin the presence of anti-A antibodies A11 
and 6E10 (ANOVA, p<0.001, Holm-Sidak Method p<0.05). 
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Interestingly, A 1-40, A 1-42 and other truncated A peptides were detected by SELDI-TOF mass 
spectrometry in CSF MVs of a patient affected by AD (Figure 4.15 III).  
 
 
 
 
 
Figure 4.15III Representative SELDI TOF MS spectra of MVs isolated from the CSF of a patient with AD showing the most common A peptides captured 
by immunoproteomic assay employing 6E10 and 4G8 monoclonal antibodies. 
 
 
Figure 4.15III Representative SELDI TOF MS spectra of MVs isolated from the CSF of a patient with AD showing the most common A peptides 
captured by immunoproteomic assay employing 6E10 and 4G8 monoclonal antibodies. 
 
 
4.16 Subchronic treatment with the MV shedding inhibitor FTY720 improves memory performance 
in APP/PS1 transgenic mice model for AD. 
It has been previously shown by our lab that MV shedding is inhibited by blockers of acid 
sphingomyelinase (A-SMase), such as imipramine or FTY720 and is almost abolished in A-SMase 
knock out glial cells in vitro and in vivo (Bianco, et al., 2009; Verderio et al., 2012). To explore the 
therapeutic potential of inhibition of MV shedding in vivo, FTY720 (1mg/Kg) or plain water were 
administered by oral gavage to 12 months-old APPswe/PS1 and their littermates for 6 weeks. Pre-
drug and post-drug behavioural tasks were carried out to test learning and different forms of 
memory performance, i.e., reference, object and innate memory, using the passive avoidance, the 
object recognition and the nest building tasks, respectively.  As expected, male APPswe/PS1 mice 
showed severe deficits in reference memory in the passive avoidance task and after 5 weeks of 
treatment with plain water performed significantly worse, as indicated by the decreased latency to 
enter the dark room, where mice receive a mild foot shock, while their cognitive performance was 
preserved upon treatment with FTY720 (Figure 4.16b-c; blue bars). These results were supported 
by object recognition memory testing, which showed reduced recognition index in vehicle-treated 
APPswe/PS1mice and improved recognition index in FTY720-treated double transgenic mice (Figure 
4.16b-c; blue bars). Female APPSwe/PS1 mice were partially protected from memory impairment 
Aβ 1-42 
Aβ 1-40 
Aβ 1-38 
Aβ 1-39 Aβ 1-37 Aβ 1-18 
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(Figure 4.16b-c; red bars).  They were never impaired in the passive avoidance task, but became 
impaired in the object recognition task after 5 weeks of treatment with plain water, while 
maintained performance similar to wild type littermates upon FTY720 administration. Consistent 
with a therapeutic action of FTY720, in the nest building task a significantly higher percentage of 
APPSwe/PS1 mice was able to complete the nest after treatment with the drug, as compared with 
pre-drug behavioural analysis (Figure 4.16d). In this task, no major difference in the behaviour of 
male and female APPSwe/PS1 mice was observed. 
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Figure 4.16 Transgenic APPPS1 Mice administered with FTY and observed for behavior tasks related to memory. A Diagrammatic representation  of  
the scheme followed for drug administration and further experiments .The mice were initially checked for their general health, reflex, sensory abilities 
and then tested for motor activity and learning and memory performance before drug administration. APPswe/PS1 displayed normal gross behavior 
and motor activity. B Passive avoidance test showed improvement with FTY720 administration, in case of APPPS1 transgenic males.  Females were 
not impaired for this test and performed like WT female controls. C Object Recognition Test was performed, initially only the transgenic male were 
impaired compared to WT control males, in course of drug/vehicle administration for 5 weeks both male and female transgenic animals, which 
received water as vehicle were impaired with respect to respective controls but transgenic animals administered with FTY720  showed significant 
improvement in their performance. D In case of Nest building, there was impairment in performance of Transgenic APPPS1 mice, both male female 
as compared to respective WT controls. We further observed improvement in performance in transgenic mice after FTY720 administration as 
compared to WT controls. The results obtained in case of male and female were similar, so the data was pooled and grouped as WT and APPPS1. 
 
4.17 FTY720 reduces inflammation in APPPS1 transgenic mice brain  
We next examined the impact of subchronic FTY720 treatment on brain inflammation. As a measure 
of astrogliosis we analyzed the mRNA (Figure 4.17a) and protein (Figure 4.17c) expression of the 
astrocytic marker GFAP in the cortex of mice. Due to differences in the behavior responses we 
analysed separately male and female both in wild type and transgenic mice.  The transgenic mice, 
especially females, showed increased levels of GFAP transcript. Interestingly, we observed that 
GFAP was significantly decrease both at mRNA and protein levels in case of male and female 
transgenic mice administered with FTY720 as compared to transgenic mice receiving vehicle alone. 
We also performed immunostaining for GFAP of the cortical slices of transgenic and wild type mice 
(Figure 4.17b). Tthis analysis was performed only in male transgenic and wild type mice and further 
indicated a significant increase in astrogliosis in transgenic mice administered with vehicle, and a 
significant decrease in GFAP protein expression upon FTY720 treatment in transgenic mice.   
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Figure 4.17 I A  Increased mRNA expression of GFAP in APPSwe/PS1 transgenic mice as compared to wild type control, which was decreased both in 
case of male and female upon FTY administration.  B Representative image of cortical section for transgenic mice showing astogliosis, the results are 
in accordance with GFAP mRNA expression. C Representative western blot for GFAP, the values obtained were normalized with Calnexin. We observed 
increased astogliosis in transgenic mice compared to wild type both in case of male and female, and decreased significantly with FTY720. 
 
 
We also observed that APPSwe/PS1 mice, especially females (Figure 4.17IIa), displayed higher mRNA 
expression of the microglial marker IBA1 in the cortex as compared to wild type littermates, and 
that upon FTY720 administration this expression was decreased. However, immunohystochemical 
analysis revealed no changes in IBA1 expression in the cortex of APPSwe/PS1mice treated with 
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FTY720 as compared to vehicle-treated mice (Figure 4.17IIb). We also analyzed by western blotting 
MCH class II molecules expression to quantify the activation of microglial towards M1 phenotype. A 
marked increase in MHCII levels was observed in female APPSwe/PS1 mice as compared to wild type 
animals. Administration of FTY720 significantly decreased MHCII expression in APPSwe/PS1 mice. 
Male APPSwe/PS1 mice showed no changed in MHCII expression with respect to control male mice 
(Figure 4.17IIc). 
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Figure 4.17 I A  Increased mRNA expression of IBA1 in APPSwe/PS1 transgenic mice as compared to wild type control, which was decreased both in 
case of male and female upon FTY administration.  B Representative image of cortical section for transgenic male mice showing microgliosis. 
Quantification of images revealed significant increase in IBA positive cells around the plaque in transgenic mice as compared to wild type, but no 
decrease was observed upon FTY administration.  C Representative western blot for MHCII, a marker to study microglial activation. The values 
obtained were normalized with Calnexin. We observed increased microglial activation in female transgenic mice compared to wild type which 
decreased significantly with FTY720. No changes were observed for MHCII in male transgenic and wild type mice. 
C tr l C tr l+ F T Y A P P S 1 A P P S 1 + F T Y
-3 ,0
-2 ,5
-2 ,0
-1 ,5
-1 ,0
-0 ,5
0 ,0
0 ,5
1 ,0
1 ,5
2 ,0
2 ,5
F
o
ld
 C
h
a
n
g
e
 (
lo
g
2
)
C tr l C tr l+ F T Y A P P S 1 A P P S 1+ F T Y
-1 ,5
-1 ,0
-0 ,5
0 ,0
0 ,5
1 ,0
1 ,5
2 ,0
2 ,5
3 ,0
3 ,5
F
o
ld
 C
h
a
n
g
e
 (
lo
g
2
)
Male 
Female 
FTY720
0 
MHCII 
Calnexin 
 H20                       FTY720 
 WT        APPS1        WT     APPS1 
Male Female 
 WT           WT       APPS1      APPS1  WT           WT       APPS1      APPS1 
FTY720
0 
 
-     +           -             + -     +           -             + FTY720
0 
 
C 
B A 
54 
 
Treatment with FTY720 also lead to   a significant reduction in the mRNA expression of typical inflammatory 
markers, i.e. iNOs, COX-2 IL-1 and IL-6  as observed independently in male and female in wild type and 
double transgenic mice. (Figure 4.16 IIIa).  
 
 
 
 
 
 
 
 
 
Figure 4.16 III A FTY induces reduction in mRNA expression of inflammatory markers in male and female both in case of wild type and APPSwe/PS1 
transgenic mice. 
 
4.18 FTY720 decreases A 1-42 load in APPPS1 transgenic mice brain. 
We further investigated if FTY720 influences the Alevels in APPSwe/PS1 transgenic mice. To 
evaluate the changes in total Abeta 1-42 levels we performed dot blot analysis from the total protein 
isolated from the cortices of transgenic mice treated or not with FTY720.  We observed that 
Alevels decreased both in male and female APPSwe/PS1 mice administered with FTY720 (Figure 
4.18a) Next we analysed by Elisa the levels of A in the soluble fraction isolated in detergent-free 
buffer from the hippocampus of APPSwe/PS1 mice chronically administered with FTY720 or plain 
water. This analysis revealed a significant decrease in soluble Alevels in female transgenic mice 
administered with FTY720. No significant changes were observed in male transgenic mice upon 
FTY720 administration (Figure 4.18b). 
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Figure 4.18 A Quantification for the total amount of A through dot blot in cortex of transgenic male and female mice revealed a decrease upon FTY 
administration. B Representative image of the Dot Blot. C Quantification for soluble Athrough ELISA in the hippocampus of transgenic male and 
female mice. We observed a significant decrease in female transgenic mice upon FTY administration, whereas male transgenic mice with and without 
FTY administration showed no differences in soluble A levels. 
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                                                                                5.  DISUSSION 
 
 
In the present study, we unveil a novel mechanism by which microglia derived MVs contribute to 
neuronal damage in AD. The effect is mediated by lipid component of MVs which changes the 
equilibrium of soluble and insoluble A 1-42, promoting formation of soluble neurotoxic species. 
The species of A 1-42 so generated bind efficiently to subpopulation of neuronal cultures, 
increasing NMDA receptor permeability and excitotoxicity. This binding was greatly prevented by 
pre-incubations with PrPC and anti-Aantibodies. We also demonstrated that Microglial MVs 
contains neurotoxic Agenerated from A 1-42 internalized by phagocytising microglia. These MVs 
can act as carrier of toxic Aand eventually may be toxic to neurons they encounter on their way. 
Furthermore we observed increased level of IB4 positive MVs in CSF obtained from AD patients. In 
line with our in-vitro data MVs from CSF of AD patients were able to promote formation of soluble 
A 1-42 and were toxic to cultured neurons. Administration of FTY720, an inhibitor of MVs shedding 
for a period of 5 weeks improved cognitive impairment in APPSwe/PS1 transgenic mice by 
decreasing level of neuroinflammation and plaque load. 
 
5.1 Microglia derived MVs increased the toxicity of A 1-42 which is mediated by the lipid 
component of MVs. 
Microglial MVs can play physiological role by modulating synaptic activity and neurotransmission 
(Antonucci, et al., 2012; Turola, et al., 2012). Moreover MVs have been identified as a novel 
biomarker of brain inflammation in humans (Verderio C, et al., 2012; Colombo E,et al., 2012).  Recent 
literature suggests alterations in metabolism of natural sphingolipids and gangliosides in AD patients 
(Mielke M M, et al., 2011) altered levels of these bioactive lipids can destabilize and rapidly 
resolubilize long  A  fibrils to neurotoxic amyloid species. We demonstrated for the first time that 
MVs, extracellularly released by cultured microglia, strongly increase A 1-42 neurotoxicity in vitro. 
This effect is due to the lipid components of MVs, which promote formation of small soluble 
neurotoxic species from A 1-42 extracellular aggregates. We observed that overnight incubation 
of inert A 1-42 peptide with microglial MVs promoted formation of soluble neurotoxic species, 
whereas A 1-42 alone became aggregated and displayed low toxicity. The A 1-42 species 
generated in A 1-42/MVs mix induced fragmentation of dendrites and reduced synaptic density as 
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compared to control cultures. Our data suggest that a transient interaction takes place between 
MVs and Abeta species, as suggested by increased A flotation on sucrose gradient upon acute 
addition of MVs. However this interaction is not stable as the neurotoxic forms generated in the 
presence of MVs are recovered in the soup after fractionation of Abeta/MVs mixture at 10000g, 
while the pellet, containing MV-associated A 1-42 along with aggregated A 1-42 forms displayed 
low toxicity and little neuronal binding capacity. This indicates that most of neurotoxic forms do not 
bind to MVs strongly. We therefore identified microglial MVs as the endogenous source of bioactive 
lipids, which are able to shift the equilibrium towards toxic A species. This argument is in line with 
previous studies that demonstrated that brain membrane lipids, including phosho- and 
(glycol)sphingolipids, favour formation of soluble forms, either promoting solubilization of inert 
fibrils (Martins JC, et al., 2008), or hindering their conversion to insoluble fibrils (Johansson A S, et 
al., 2007). Interestingly, neuronal exosomes have been found to promote rather than reduce 
Afibrillogenesis (Yuyama K, et al., 2012), thus indicating that lipid composition of MVs generated 
from distinct cell types may have different effects on Aextracellular assembly and can influence 
the kind of species generated. Notably, MVs have a distinct repertoire of lipids not only compared 
to exosomes (our unpublished data) (Thery C., et al. 2009) but also to the plasma membrane of 
origin. MVs are enriched in cholesterol, sphingomyelin and ceramide and contain lipid raft elements 
(Del Conde I, et al., 2005), including GM1 and GM3 gangliosides and flotillin-2 (Han X, et al., 2003). 
Interestingly, artificial liposomes, that mimic the phospholipids composition of the plasma 
membrane, neither induce fibril solubilization nor promote Aneurotoxicity. Lipidomic profiling of 
microglial MVs will be of help to better characterize the endogenous lipids responsible for the 
generation of neurotoxic A species, which could themselves represent putative AD biomarkers 
(Serrano-Pozo A, et al., 2012; Han X, et al., 2003; Malnar M, at al., 2012). 
 
5.2 Toxicity of A 1-42/MVs mixture is due to soluble A 1-42 species, and is neutralized by PrPC 
and anti- A 1-42 antibodies. 
The majority of neurotoxic A 1-42 generated in A 1-42/ MVs mix, is retained in the soup after 
partitioning of A 1-42/ MVs in two fraction by ultracentrifugation. They are soluble, non-
aggregated A 1-42 species, which are not associated to MVs as indicated by our previous 
observations. Electron microscopic images confirmed the presence of globular structures of 
diameter between 4 and 8 nm, similar to those of oligomeric A 1-42. The toxicity of small soluble 
Aspecies has been proposed to depend on their interaction with specific neuronal proteins, 
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such as the NMDA receptor (Synder E M, et al., 2005) or the prion protein PrPC (Lauren J, et al.,2009), 
which modulates NMDA receptors through Fyn kinase (Um JW, et al., 2012). Alternatively, soluble 
Aoligomers may damage neurons by binding to multiple membrane components, including 
lipids, thereby changing membrane permeability and causing calcium ion leakage into the cell 
(Benilova I, et al.,2012; Verdier Y., et al., 2004) We demonstrated that the soluble forms generated 
in A 1-42/ MVs mix, bind efficiently to a subpopulation of neurons in vitro, and increase NMDA 
receptor permeability causing an excitotoxic damage. This response was blocked when the 
antagonist of NMDA receptor APV was administered to the neuronal cultures.  We excluded that 
toxicity could be due to glutamate content of MVs or A 1-42/MVs preparation, as we detected a 
glutamate concentration in A 1-42/MVs much below the minimum required for activation NMDA 
response. We observed significant reduction in binding of soluble A 1-42 to neurons in the 
presence of PrPC thanks to the competition between Abinding to dendrites and to PrPC, 
which is a high affinity receptor for oligomeric ABinding of soluble A 1-42 was completely 
abolished by a cocktail of anti-A antibodies. This reduction in binding of soluble A 1-42 by PrPC 
and anti- A antibodies could neutralize the neurotoxicity caused by A 1-42/MVs mix. 
 
5.3 Microglial MVs contain toxic A  forms generated from internalized A 1-42.  
First we demonstrated that microglia-derived MV mediate extracellular A processing, leading to 
neurotoxicity. Then, we could show that microglial MVs also contain toxic forms generated from 
internalized A Previous literature indicates that exosomes derived from neurons and 
oligodendrocytes carry a fraction of intracellular A (Rajendran L., et al.,2006; Gidhoni R, et al.,2011; 
Vingtdeux V, et al., 2007) and that phagocytosed  Acan be re-secreted from microglia, although 
through an unknown mechanism (Yamamoto, et al., 2008). In our study we demonstrated that 
microglia release neurotoxic A1-42 and A1-40 species in association with MVs. This is the first 
evidence that microglia, which phagocytize and degrade extracellular A fibrils (Aguzzi A, et al., 
2013; Prinz M, et al.,2011) or cause macropinocytosis of soluble A (Paresce DM., et al.1997; Lee 
CY., et al. 2010) can favour seeding and formation of neurotoxic amyloids throughout the brain. We 
assume that when there is saturation of A degradation pathways, due to excessive abeta load, 
beyond the clearing capacity of microglia, these cells can eliminate undigested Athrough the 
release of MVs. In this way, MV-mediated release of neurotoxic A forms may occur. Neurotoxic A 
species may be processed in early to late endosomes and lysosomes ( Rajendran L, et al.,2012), after 
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disassembly of phagocytosed A. Sorting to the external surface of MVs can occur through 
association with the GPI-anchored protein PrPC or GM1 gangliosides, all of which are localized to 
raft domains (Mattei V, et al., 2009) and bind tightly to A oligomers (Ariga T., et al 2001). 
Alternatively, neurotoxic forms may be generated at the plasma memnbrane of microglial cells. 
Indeed the microglial surface  contains components of the ɣ-secretase complex -also localized inside 
lipids rafts (Rajendran L, et al., 2012 ) and can cleave the carboxyl terminal of A 1-42 at position 40 
(Kiyota T, et al., 2009), resulting in the generation of neurotoxic A species. This sorting mechanism 
may be consistent with the proposed role of lipid rafts in setting up platforms to concentrate into 
MVs proteins destined to secretion (Shen B, et al., 2011; Del Conde I, et al., 2005). The fact that we 
observed significant decrease in neurotoxicity upon pretreatment with anti-A antibodies strongly 
supports the theory that neurotoxic A forms are localized to the outer lipid bilayer of MVs. Finally, 
we cannot exclude that processing of A1-42 to A1-40 may even proceed within MVs. Indeed, 
previous evidence showed that neuron-derived EMVs contain some components of the ɣ -secretase 
complex (Sharples RA, et al.,2008), while the Insulin Degrading Enzyme IDE, which proteolyzes A 
1-42 and A 1-40, has been detected among cargo proteins of microglial EMVs (Tamboli IY, et al., 
2010). However, further studies are required to unequivocally define the topology of A species and 
to clarify whether A forms are actually associated to the extracellular membrane of shed MVs. 
 
5.4 Microglial MVs in CSF of AD patients. 
The in-vitro findings of my thesis work has clear clinical implications. The main idea behind the 
hypothesis that microglia-derived MVs can lead to neurotoxicity came from the fact that both in AD 
patients and mice models for AD there are activated microglial cells surrounding the plaque. Recent 
studies demonstrates that activation of microglia increases linearly throughout the disease course 
and correlates with AD neurodegeneration (Serrano-Pozo A, et al., 2011). These activated microglia 
cells release MVs, so we were interested in investigating the production of MVs in AD patients. 
Interestingly we found that microglial MVs were very high in MCI and AD patients, reflecting 
microgliosis (Verderio C, et al., 2012), which typically characterizes the disease (Serrano-Pozo A, et 
al., 2011). In accordance with our in-vitro results we observed that MVs collected from the CSF of 
AD patients promote extra-cellular formation of neurotoxic A species, similarly to MVs shed from 
cultured cells. We also found that the MVs from AD patients were extremely toxic to cultured 
neurons, more than Mvs collected from patients with other neuroinflammatory disorders, and by 
the use of anti-Aantibodies we could partially block this toxicity. These results suggest that the 
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toxicity of MVs from AD patients is at least in part, associated to their A cargo. Further analysis of 
the various A species present in the MVs obtained from the CSF of a large cohort of AD and healthy 
subjects will clarify whether changes in the conformation and/or in the amount of Aforms may 
account for higher neurotoxicity of MVs from dementia patients. Furthermore, lipidomic profiling 
of human MVs from AD and healthy subjects will help to understand if possible alterations in lipid 
components can in part account for neurotoxicity caused by MVs from AD patients and may be used 
as a new putative AD biomarkers, thus increasing the diagnostic potential of MVs in AD. Finally, it 
should be pointed out that it is still to be defined whether MVs may associate with Abeta present in 
the parenchyma/blood vessel as well as plaques during their travel to CSF. In this case the content 
of Abeta present in MVs collected from dementia patients does not merely reflect Abeta trafficking 
inside donor microglial cells.  
 
In agreement with their pathogenic role, levels of microglia-derived MVs are positively correlated 
with classical biomarkers of neuronal injury such as tau in the CSF (Holtzma D, et al., 2011) of MCI 
and AD subjects, and with damage to white matter structures of the temporal lobe in MCI patients, 
as revealed by MRI scans (Dalla Libera, et al., manuscript in preparation). These observations 
suggest that MVs may play a critical role in AD pathogenesis and open the way for new therapies 
targeting MVs to prevent neurotoxicity of A species in the brain. Moreover our study suggests that 
MVs may represent as a novel companion tool for AD diagnosis.  
 
5.5 Treatment with the inhibitor of MV shedding FTY720 improves cognitive impairment in 
APPSwe/PS1 transgenic mice by decreasing neuro-inflammation and plaque load. 
We further observed that treatment with the pharmacological drug FTY720, which is known to exert 
therapeutic benefit in MS (Cohen JA, et al.,2011) and various CNS injuries, such as stroke and trauma 
(Aktas O, et al., 2010; Wei Y, et al., 2011) could ameliorate the pathophysiology and cognitive 
defects in APPSwe/PS1 AD mouse model. Recent reports suggest that FTY720 is a specific inhibitor 
of A-SMase (Dawson G, et al., 2011), the enzyme that controls MV production. Work from our lab 
further demonstrated that FTY720 completely abolished release of MVs evoked by ATP in vitro and 
decreased MV concentration to baseline levels in the CSF of EAE mice upon chronic treatment 
(Verderio C, et al., 2012). Thus, we were interested to explore the possibility that inhibition of MV 
shedding by FTY720 may contribute, at least in part, to the therapeutic action of FTY720 in the brain. 
To investigate this possibility we used APPSwe/PS1 transgenic mice as a model of AD.  
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As expected, we observed cognitive impairment in male APPswe/PS1 mice in passive avoidance and 
object recognition memory tests as compared to wild type mice. Transgenic females were not 
impaired in passive avoidance, but became impaired in object recognition during the course of 
treatment with the vehicle. Notably we observed a promising improvement in the cognitive 
behaviour of transgenic male and female mice upon FTY 720 administration for 5 weeks. However 
we could not correlate amelioration of cognitive behaviour to variation in MV production by the 
drug, as in the old mice used in these experiments we did not collected sufficient amount of CSF to 
analyse MV concentration by FACS. 
Consistent with the known immunosuppressive properties of the drug (S Suzuki, et al., 1996), we 
found a significant reduction in astrogliosis and microgliosis in the brain of transgenic mice treated 
with FTY720, which tipically display increased protein and mRNA levels of the astrogliosis and 
microgliosis marker GFAP and IBA1. Indeed there was a significant reduction in mRNA expression of 
these inflammatory markers in transgenic mice upon FTY treatment. The wild type mice 
administered with FTY performed poorly in behaviour and there was further reduction in glial cells 
along with decrease in inflammatory marker as compared to wild type littermates administered with 
water. There is evidence showing that S1P influences inflammatory responses and induces neuronal 
apoptosis in a concentration-dependent manner (Hagen, et al., 2009). Therefore, it may be 
hypothesized that administration of FTY720 to non-AD mice enhances the S1P signalling to 
pathologic levels. In addition, we observed decreased level of total abeta load upon FTY720 
treatment in transgenic mice, while soluble abeta brain content was significantly decreased in case 
of transgenic female.  
Recently a lot of reports point to multiple molecular targets of FTY720 neuroprotective action. The 
phosphorylated form of FTY is an analog of S1P. In AD patients, levels of SIP are significantly reduced 
compared with the age-matched normal controls. FTY720 also decreases the levels of ceramides (S 
Lahiri, et al.,2009), which have been shown to promote beta amyloid peptide formation and are also 
linked to neurotoxicity via activation of pro-apoptotic pathways (X. He, et al., 2010) Furthermore 
SPK1 (S1P producing enzyme) overexpression, promotes neuronal survival upon A exposure (A. 
Gomez-Brouchet, et al., 2007). Ex vivo study, demonstrates that S1P possesses neuroprotective 
effects against soluble Aβ oligomer-induced cell death by inhibiting the activation of acid 
sphingomyelinase (Gómez-Muñoz, et al., 2003). The balance between the levels of ceramide and 
S1P, the ‘ceramide/S1P rheostat’, contributes to the fate of cells (Cuvillier, et al., 1996). Therefore, 
the potential ability of FTY720 to recapitulate the function of S1P might also underlie its protective 
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mechanism against Aβ neurotoxicity, which can account for behavioural improvement in transgenic 
mice treated with FTY.  
Recent reports also indicate that FTY720 may also act directly on neural and non-neural CNS cells to 
reduce Abeta neurodegeneration and to promote reparative mechanisms through upregulation of 
BDNF production (Doi Y, et al., 2013). In   parallel to our study, other groups observed that chronic 
treatment with FTY720 decreases the Aβ42-induced activation of caspase-3 and protects against 
hippocampal neuronal loss in vitro (Fatemeh Hemmati, et al. 2013). The protective actions of FTY720 
also manifest as improved spatial learning and memory formation in AD model rats. It has been 
suggested that FTY720 administration improves passive avoidance memory retrieval through 
mechanisms which alter the overall inflammatory and apoptotic mechanisms toward less brain 
damage and memory loss (Fatemeh Hemmati, et al. 2013).  
In conclusion, although we observed a clear improvement in the pathophysiology and cognitive 
defects of APPSwe/PS1 AD mice upon FTY720 administration, due to the multiple targets of the 
drug, we could not ascribe its neuroprotective action to its ability to inhibit MV shedding. Actually 
we believe that FTY720 may induce beneficial effects in AD by multiple pathways and either 
improving or preventing the patology from father progression. 
 
5.6 Conclusion 
Our study clearly demonstrates that MVs derived from microglial cells, surrounding the plaque may 
act as a carrier of neurotoxic species and have potential to convert extracellular inert  to 
neurotoxic. The increase in level of myeloid MVs in CSF of AD patient, identifies MVs as a novel 
therapeutic target and companion tool for AD diagnosis. 
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1. AD:           Alzhheimer’s Disease 
2. Aβ:          Amyloid beta 
3. MVs:        Microvesicles 
4. CAA:       Congophilic amyloid angiopathy  
5. ER:           Endoplasmic Reticulum 
6. APP:       Amyloid precursor protein 
7. BACE-1: β-site APP-cleaving enzyme  
8. CTF:       C-terminal APP fragment  
9. APH-1:   Anterior pharynx-defective phenotype 1 
10. PEN-2:   PS-enhancer 2 
11. AICD:     APP intracellular domain  
12. GAGs:    Glycosaminoglycans  
13. apoE :    apolipoprotein E  
14. SAP :      Serum amyloid P  
15. IFN :       Interferon  
16. MHC :    Major histocompatibility complex,  
17. TNF-α :  Tumor necrosis factor-α  
18. MVBs :   Multivesicular bodies  
19. ESCRT:   Endosomal sorting complex required for transport 
20. CHMPs : Charged multivesicular body proteins  
21. IL-1β:      Interleukin-1β  
22. IL-6:        Inteleukin-6  
23. CNS:       Central nervous system 
24. mEPSC:  Miniature excitatory post-synaptic current  
25. CSF:        Cerebrospinal fluid  
26. MCI:       Mild cognitive impairment 
                                                                             8.  ABBREVIATIONS 
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27. BBB:       blood−brain barrier  
28. BDNF:    Brain-derieved neutotrophic factor 
29. MWM:   Morris water maze  
30. DMSO:   dimethyl sulfoxide  
31. HFP:       hexafluoroisopropanol  
32. ThT:       Thioflavin-T  
33. PI :         propidium iodide  
34. TBST:     tris buffered saline with tween-20  
35. CHCA:    α-cyano-4-hydroxy cinnamic acid  
36. SSc:        side-scatter  
37. EM:        Electron microscopy  
38. HC:         healthy controls  
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